



# 7<sup>th</sup> World Congress on ADHD

From Child to Adult Disorder

25 – 28 April 2019

Lisbon | Portugal



**FINAL PROGRAMME**

[www.adhd-congress.org](http://www.adhd-congress.org)

# TABLE OF CONTENTS

|  | Page |
|--|------|
| <b>Welcome Address</b> .....                       | 3    |
| <b>Organization</b> .....                          | 4    |
| <b>Committees</b> .....                            | 5    |
| <b>World Federation of ADHD</b> .....              | 6    |
| <b>Overview of Meeting Rooms</b> .....             | 7    |
| <b>Format Descriptions</b> .....                   | 9    |
| <b>Programme Overview</b> .....                    | 10   |
| <b>CME Credits</b> .....                           | 13   |
| <b>Scientific Programme</b>                        |      |
| Thursday, 25 April 2019 .....                      | 14   |
| Friday, 26 April 2019 .....                        | 17   |
| Saturday, 27 April 2019 .....                      | 28   |
| Sunday, 28 April 2019 .....                        | 39   |
| <b>Patients' Day</b> .....                         | 40   |
| <b>Educational Seminars</b> .....                  | 41   |
| <b>Meet-the-Expert-Sessions</b> .....              | 43   |
| <b>General Information</b> .....                   | 47   |
| <b>Satellite Symposia</b> .....                    | 51   |
| <b>Acknowledgements</b> .....                      | 51   |
| <b>Exhibition Map and List of Exhibitors</b> ..... | 52   |
| <b>List of Chairpersons and Presenters</b> .....   | 53   |

## CONGRESS APP

Get the 7<sup>th</sup> World Congress on ADHD APP for your smart phone now and experience the congress at your fingertips! Quickly find your way through the most up-to-date congress schedule. Stop carrying around piles of paper. Just take the congress with you, wherever and whenever you want! The APP is completely free and provides iPhone / iPad and Android smartphones users at the 7<sup>th</sup> World Congress on ADHD 2019 in Lisbon.



The ADHD 2019 APP is powered by GLOBIT GmbH in cooperation with esanum GmbH.

Further information is given at

[www.adhd-congress.org/app/mobile](http://www.adhd-congress.org/app/mobile)



## WELCOME ADDRESS



Luis A. Rohde

Dear Colleagues and Friends,

On behalf of the World Federation of ADHD, we are pleased to welcome you to our 7<sup>th</sup> World Congress on ADHD – From Child to Adult Disorder in Lisbon, Portugal, from 26 to 28 April.

Looking forward to see you in Lisbon, the capital and largest city of Portugal, with an estimated population of half a million residents. Lisbon is recognised as an "alpha-level global city" because of its importance in finance, commerce, media, entertainment, arts, international trade, education and tourism. The congress center is located close to the river Tagus and the historical district and cultural heritage of Belem, just a few minutes from the city center, in a prime area with a vast transport supply. It is a perfect venue for the upcoming 7<sup>th</sup> World Congress on ADHD .



Manfred Gerlach

Every second year, our World Congress attracts numerous delegates from all over the world who want to learn about the latest research findings and perspectives on ADHD. You are cordially invited to attend lectures of world-renowned speakers, presenting the most recent information on ADHD and related disorders, and to share experiences and knowledge with old and new friends.

The Scientific Programme Committee has once again created an excellent scientific programme, consisting of outstanding Plenary Lectures, parallel Hot Topic and Research Consortia Symposia, Late Breaking News, a Grand Round, a Pro and Con Debate, and Guided Poster Tours. Furthermore, in order to guarantee a more individualized and interactive atmosphere, we invite you to attend our Educational Seminars and Meet the Expert Sessions, which will take place in the afternoons.

Of the more than 100 abstracts submitted by young scientists, the best eight have been selected by the Scientific Programme Committee. The authors were invited to give a presentation as part of our two Young Scientist Sessions. With this approach, we intend to emphasise the importance of original scientific contributions by our young colleagues at the congress.

We are pleased to have received more than 180 poster abstracts. To make sure that the presentations of the different topic categories can be represented uniformly, we have organised altogether 29 Guided Poster Tours. We would like to encourage you to not only view these selected posters, but to also engage in active discussions and to exchange ideas with our young colleagues.

We want to thank all the speakers, contributors and sponsors. We look forward to welcoming you in Lisbon and hope that you will enjoy our exceptional scientific programme. We promise you an unforgettable learning experience with the most recent and authoritative information on all aspects of ADHD.

Thank you very much for your participation!

With kind regards,

Luis A. Rohde  
Congress President  
President WFADHD

Manfred Gerlach  
Chairman Scientific  
Programme Committee



## ORGANIZATION

### CONGRESS PRESIDENT

Luis A. Rohde  
Federal University of Rio Grande do Sul  
90040-060 Porto Alegre, Brazil  
Email: [adhd2019@cpo-hanser.de](mailto:adhd2019@cpo-hanser.de)

### CHAIRMAN SCIENTIFIC PROGRAMME COMMITTEE

Manfred Gerlach  
University of Würzburg  
97080 Würzburg, Germany  
Email: [adhd2019@cpo-hanser.de](mailto:adhd2019@cpo-hanser.de)

### CONGRESS VENUE

Lisbon Congress Center  
Praca Industrias  
Lisbon 1300-307, Portugal

### ORGANIZER

**World Federation of ADHD**  
Global Head Office  
Zum Ehrenhain 34  
22885 Barsbüttel, Germany  
Phone: +49-40-670 88 20  
Fax: +49-40-670 32 83  
Email: [adhd@cpo-hanser.de](mailto:adhd@cpo-hanser.de)

### CONGRESS AND EXHIBITION OFFICE

**CPO**<sup>®</sup>  
**HANSER**  
SERVICE

**Hamburg Office**  
Hanser & Co GmbH  
Zum Ehrenhain 34  
22885 Barsbüttel, Germany  
Phone: +49-40-670 88 20  
Fax: +49-40-670 32 83  
Email: [adhd2019@cpo-hanser.de](mailto:adhd2019@cpo-hanser.de)



**REGISTER NOW**



# Welcome to Vancouver

WFSBP Congress 2019

## 14<sup>th</sup> World Congress of Biological Psychiatry

2 – 6 June 2019 | Vancouver, Canada  
[www.wfsbp-congress.org](http://www.wfsbp-congress.org)

## SCIENTIFIC PROGRAMME COMMITTEE

---

**Chair:** M. Gerlach, Germany  
 P. Asherson, United Kingdom  
 T. Banaschewski, Germany  
 M. Bellgrove, Australia  
 J. Biederman, USA  
 J. Boavida, Portugal  
 J. Buitelaar, The Netherlands  
 F. X. Castellanos, USA  
 D. Coghill, United Kingdom  
 M. Döpfner, Germany  
 D. Fair, USA  
 S. Faraone, USA  
 B. Franke, The Netherlands  
 C. Freitag, Germany  
 S. Gau, Taiwan  
 J. Halperin, USA  
 S. Kasper, Austria  
 S. Kollins, USA  
 S. Kooij, The Netherlands  
 J. O. Larsson, Sweden  
 K.-P. Lesch, Germany  
 I. Manor, Israel  
 G. Mattingly, USA  
 A. Miranda, Spain  
 J. Newcorn, USA  
 J. Nigg, USA  
 A. Philipsen, Germany  
 D. Quinn, Canada  
 J. A. Ramos-Quiroga, Spain  
 A. Reif, Germany  
 F. W. Reimherr, USA  
 P. Riederer, Germany  
 L. A. Rohde, Brazil  
 K. Rubia, United Kingdom  
 T. Saito, Japan  
 R. Schachar, Canada  
 P. Shaw, USA

D. Silva, Australia  
 M. Solanto, USA  
 E. Sonuga-Barke, United Kingdom  
 C. Soutullo, Spain  
 M. Stein, USA  
 J. Swanson, USA  
 J. Thome, Germany  
 O. Tucha, The Netherlands  
 G. van de Glind, The Netherlands  
 S. Walitza, Switzerland  
 Y. Wang, China  
 A. Warnke, Germany  
 M. Weiss, Canada  
 Y. Zheng, China  
 A. Zuddas, Italy

## LOCAL ORGANIZING COMMITTEE

---

**Chair:** J. Boavida, Portugal  
 A. Ponte, Portugal  
 A. Rodrigues, Portugal  
 P. Cabral, Portugal  
 C. Filipe, Portugal  
 J. Cerejeira, Portugal  
 J. Guerra, Portugal  
 T. Cartaxo, Portugal  
 C. Sotullo, Spain  
 B. Barahona Corrêa, Portugal  
 M. Pinto, Portugal

## POSTER COMMITTEE

---

**Chair:** O. Tucha, The Netherlands  
 S. Dasgaard, Denmark  
 A. Fuermaier, The Netherlands  
 G. Polanczyk, Brazil  
 C. Filipe, Portugal

## WORLD FEDERATION OF ADHD

In August 2008, the World Federation of ADHD (Attention-Deficit/Hyperactivity Disorder) and allied disorders was founded in Zurich, Switzerland. Andreas Warnke, former Director of the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy at the University of Würzburg, Germany, was officially nominated the first president of this non-profit organisation.

The purpose of the World Federation of ADHD and allied disorders is to support and promote clinical studies, scientific projects and training programmes in the field of ADHD and related disorders worldwide, as well as to enhance the exchange of information between scientists, physicians, health experts, ADHD lay organisations and the public.

In addition to achieving these goals, every second year, the World Federation of ADHD holds the World Congress which attracts numerous delegates from all over the world who want to learn about the latest research findings and perspectives on ADHD.

### **World Federation of ADHD, Global Head Office**

CPO HANSER SERVICE  
Zum Ehrenhain 34  
22885 Barsbüttel, Germany

Phone: +49-40-670 88 20  
Fax: +49-40-670 32 83  
Email: [adhd@cpo-hanser.de](mailto:adhd@cpo-hanser.de)

**GENERAL ASSEMBLY – for members only –**  
**25 April 2019 | 12:00–13:30 | Auditorium III**

## BECOME A MEMBER NOW !


### **Advantages**

- ▶ Substantially reduced registration fees for World Congress of ADHD Congresses in Lisbon 2019 and Prague 2021
- ▶ Access to the latest abstract reviews
- ▶ A selection of the latest and most important abstract issues in seven different categories will be prepared for all members. The most efficient way to be keep updated!
- ▶ Networking with colleagues worldwide
- ▶ Reasonable annual membership fee EUR 50


▶ ▶ Visit us at [www.adhd-federation.org](http://www.adhd-federation.org)

# OVERVIEW OF MEETING ROOMS – EAST WING

## GROUND FLOOR



## FIRST FLOOR





# World Federation of ADHD

## Attention Deficit Hyperactivity Disorder

### SAVE THE DATE

we look forward meeting you at the

### 8<sup>th</sup> World Congress on ADHD

From Child to Adult Disorder

22 – 25 April 2021 | Prague, Czech Republic



[www.adhd-congress.org](http://www.adhd-congress.org)

### BENEFITS OF AN ADHD MEMBER

- Exchanging information on latest developments
- Advance the clinical and basic research
- Scientific, scholarly and educational training
- Collaboration with other related professional and lay organisations

Global Head Office and  
Congress and Exhibition Office

**CPO**<sup>®</sup>  
**HANSER**  
SERVICE

Hanser & Co GmbH  
Hamburg Office  
Zum Ehrenhain 34  
22885 Barsbüttel, Germany  
Phone: +49 – 40 – 670 882 0  
Fax: +49 – 40 – 670 32 83  
Email: [adhd@cpo-hanser.de](mailto:adhd@cpo-hanser.de)



## EDUCATIONAL SEMINARS (ES)

---

**Duration: 60 min.**

Educational Seminars are designed to be informal and interactive and feature an update on clinical, relevant topics. Each 60-minute seminar is composed of one, respectively two lectures and is followed by a discussion. To facilitate coordination, attendance is limited. Tickets are available on site at the registration counter and are handled on a 'first-come, first-served' basis.

Registration fee per session: EUR 50. Only valid in combination with the congress registration fee.

## GUIDED POSTER TOURS (P)

---

**Duration: 90 min.**

All accepted posters are presented during Guided Poster Tours. The posters are displayed in the poster exhibition. Whenever possible, the lead or senior authors should be present during the presentation. The presenting author has to be registered.

## HOT TOPIC SYMPOSIA (HT)

---

**Duration: 90 min.**

Hot Topic Symposia feature comprehensive reviews of the most recent research results as well as practical issues in the field of ADHD. Each 90-minute symposium, presented by internationally recognized clinicians and neuroscientists, contains a theme of topical interest and is composed of three or four lectures, with a maximum of 20 minutes. After the talks there will be short discussions.

## LATE BREAKING NEWS (LN)

---

**Duration: 30/90 min.**

These sessions provide a critical review of most recently published papers on ADHD, highlighting the relevance, novelty and quality.

## MEET-THE-EXPERT-SESSIONS (ME)

---

**Duration: 60 min.**

Meet-the-Expert-Sessions have been specifically designed to provide an informal atmosphere where doctors and scientists can interact with internationally renowned experts in the field of ADHD. The sessions are especially suitable for the exchange of knowledge and aim at first-hand learning about the latest clinical (practical) and scientific advancements. Meet-the-Expert-Sessions are open to all participants, but tickets are handled strictly on a 'first-come, first-served' basis.

Registration fee per session: EUR 50. Only valid in combination with the congress registration fee.

## PLENARY SESSIONS (PL)

---

**Duration: 120 min.**

Plenary Sessions feature authoritative scientific updates on a comprehensive range of topics. Each daily session is composed of three to four 30-minute lectures presented by international leaders in the field of ADHD. After the talk there will be no discussion.

## PRO-CON DEBATE (PD)

---

**Duration: 90 min.**

This session is designed to involve all attendees of the congress. Two experts debate the pros and cons of an up-to-date topic within the field of ADHD.

Views from several angles will be addressed and will be open for debate.

## RESEARCH CONSORTIA SYMPOSIA (RC)

---

**Duration: 90 min.**

These symposia provide an in-dept report of the latest research findings from international research consortia. Experts in the field of neurology and psychiatry will present new designs and findings and will discuss these issues with participants.

## ROUND TABLE (RT)

---

**Duration: 90 min.**

ADHD experts discuss a clinical case within the field of ADHD led by renowned moderator.

## YOUNG SCIENTISTS' SESSIONS (YS)

---

**Duration: 90 min.**

Young Scientists' Sessions are specifically aimed at young scientists in the field of ADHD. Selected by the Scientific Programme Committee young scientists have the possibility to present their findings. Chaired by recognized experts in the featured topic, these interdisciplinary sessions are composed of 20-minute lectures, followed by short discussions.

## INDUSTRY SPONSORED SESSIONS (SA)

---

**Duration: 60 – 90 min.**

Satellite Symposia are organized by pharmaceutical companies and are open to all congress delegates.

# PROGRAMME OVERVIEW

Thursday, 25 April 2019

| Room<br>Time | AUD I  | AUD II   | AUD III  | AUD IV  | Room 5A   | Room 5B   | Room 5C  |  |
|--------------|--|--|--|---|---|---|--|--|
| 12:00        |  |  |  |   |   |   |  | <b>Registration</b><br>10:00–19:00<br><b>Ground Floor</b><br><a href="#">Foyer C</a><br><br><b>Technical Exhibition</b><br>15:00–21:00<br><b>First Floor</b><br><a href="#">Pavilion 4</a> |
| 13:00        |  |  | <b>General Assembly</b><br>—members only—  |   |   |   |  |  |
| 14:00        | <b>HT-04</b><br>New perspectives on functional outcomes in children and adults with ADHD | <b>HT-01</b><br>What sleep have to do with ADHD and its treatment? | <b>YS-01</b><br>Young Scientists' Session I  | <b>RC-01</b><br>International collaboration on ADHD and substance abuse: New research on ADHD and substance abuse | <b>HT-05</b><br>Preterm birth and ADHD  | <b>HT-02</b><br>Seeing beyond the disorder  | <b>HT-03</b><br>Adult ADHD across Europe/World                                   |  |
| 15:00        |  |  |  |   |   |   |  |  |
|              | Coffee Break   |  |  |   |   |   |  |  |
| 16:00        | <b>HT-08</b><br>Hot-topics for the clinicians  | <b>HT-07</b><br>ADHD and problematic internet use                  | <b>RC-02</b><br>EU consortia CoCA and Eat2BeNice: The influence of food and/or physical activity on the course of ADHD |   | <b>RC-03</b><br>ADHD and its comorbidity with psychiatric and non-psychiatric disorders across the lifespan | <b>HT-06</b><br>Why guidelines give different directions for clinicians on the care and management of ADHD across the life cycle? | <b>HT-09</b><br>Attention deficits in ADHD: Assessment strategies for the clinic |  |
| 17:00        |  |  |  |   |   |   |  |  |
| 18:00        |  | <b>SA-01</b><br>Industry Sponsored Symposium                       |  |   |   |   |  |  |
| 19:00        |  | see page 51  |  |   |   |   |  |  |
| 20:00        | <b>Opening Ceremony</b>  |  |  |   |   |   |  |  |
|              | <b>20:30 – 21:30</b> Networking Reception in the exhibition area                         |  |  |   |   |   |  |  |

## Abbreviations

|           |                         |           |                              |           |                              |
|-----------|-------------------------|-----------|------------------------------|-----------|------------------------------|
| <b>ES</b> | Educational Seminar     | <b>RC</b> | Research Consortia Symposium | <b>LN</b> | Late Breaking News           |
| <b>ME</b> | Meet-the-Expert-Session | <b>PC</b> | Pro-Con Debate               | <b>P</b>  | Guided Poster Tour           |
| <b>PL</b> | Plenary Session         | <b>YS</b> | Young Scientists' Session    | <b>SA</b> | Industry Sponsored Symposium |
| <b>HT</b> | Hot Topic Symposium     | <b>RT</b> | Round Table                  |           |                              |

# PROGRAMME OVERVIEW

Friday, 26 April 2019

| Room<br>Time | AUD I  | AUD II  | AUD III  | AUD IV   | Room 5A   | Room 5B                                  | Room 5C   |   |
|--------------|--|---|--|--|---|--|---|---|
| 08:30        |  |   |  |  |   |  |   | <b>Registration</b><br>07:30 – 18:00<br><b>Ground Floor</b><br><a href="#">Foyer C</a>  |
| 09:00        | <b>PL-01</b><br>Long-term<br>benefits and<br>potential risks<br>of medical treat-<br>ments<br>for ADHD |   |  |  |   |  |   | <b>Technical<br/>Exhibition</b><br>09:00 – 17:00<br><b>First Floor</b><br><a href="#">Pavilion 4</a>                              |
| 10:00        |  |   |  |  |   |  |   |   |
| 11:00        | Coffee Break/Late Breaking News in <a href="#">Pavilion 4</a> , First Floor                            |   |  |  |   |  |   | <b>Poster<br/>Exhibition</b><br><b>First Floor</b><br>09:00 – 17:00<br><a href="#">Pavilion 5</a>                                 |
| 12:00        | <b>RT-01</b><br>Grand-round:<br>Managing<br>ADHD in<br>pre-scholars                                    |   |  |  |   |  |   |   |
| 13:00        |  |   |  |  |   |  |   | <b>SA-02</b><br>Industry<br>Sponsored<br>Symposium<br><b>Ground Floor</b><br><a href="#">Auditorium<br/>VI+VII</a><br>see page 51 |
| 14:00        |  |   |  |  |   |  |   |   |
| 15:00        | Coffee Break   |   |  |  |   |  |   | <b>Guided<br/>Poster Tours</b><br>14:30 – 16:00<br><b>P-01 to P-14</b><br><a href="#">Pavilion 5</a>                              |
| 16:00        | <b>HT-14</b><br>The controver-<br>sial use, new<br>use, and mis-<br>use of psycho-<br>stimulants       | <b>HT-12</b><br>New concepts<br>and approaches<br>to study ADHD | <b>HT-15</b><br>ADHD, autism<br>and Tourette<br>syndrome:<br>Studies on<br>overlap and<br>divergence | <b>HT-11</b><br>Hot topic in<br>research: What<br>we need in the<br>field to better<br>understand<br>ADHD? The new<br>big data...<br>studies | <b>HT-10</b><br>Who are the<br>ADHD patients<br>who respond<br>to neuro-thera-<br>pies? | <b>RC-04</b><br>Eunethydis<br>consortium | <b>HT-13</b><br>Pre-, peri- and<br>postnatal risk<br>factors in the<br>development<br>of ADHD |   |
| 17:00        |  |   |  |  |   |  |   |   |
| 18:00        |  |   | <b>ES-02</b><br>Psychoeduca-<br>tion, cognitive-<br>behavioural<br>treatment and...                  | <b>ES-03</b><br>Assessment<br>strategies of<br>ADHD in adults  |   |  |   |   |
| 18:45        |  |   |  |  |   |  |   |   |

## ADDITIONAL SESSION ROOMS

17:45 – 18:45

|           |              |  |
|-----------|--------------|--|
| Room 1.08 | <b>ME-03</b> | ADHD and giftedness  |
| Room 1.03 | <b>ME-01</b> | Why are adolescents with ADHD so hard to treat?  |
| Room 1.02 | <b>ES-01</b> | Women ADHD – specificity of symptoms   |
| Room 1.04 | <b>ME-02</b> | How do I treat patients at the Adult ADHD Program in the Massachusetts General Hospital? |

# PROGRAMME OVERVIEW

Saturday, 27 April 2019

| Room<br>Time | AUD I   | AUD III   | AUD IV  | Room 5A                                       | Room 5B  | Room 1.08   | Room 1.03  |  |
|--------------|---|---|---|---|--|---|--|--|
| 08:30        |   |   |   |   |  |   |  | <b>Registration</b><br>08:00 – 17:00<br><b>Ground Floor</b><br><a href="#">Foyer C</a>                                     |
| 09:00        | <b>PL-02</b><br>Update on<br>ADHD neuro-<br>biology and<br>pathogenesis     |   |   |   |  |   |  | <b>Technical<br/>Exhibition</b><br>09:00 – 17:00<br><b>First Floor</b><br><a href="#">Pavilion 4</a>                       |
| 10:00        |   |   |   |   |  |   |  |  |
| 11:00        | Coffee Break/Late Breaking News in <a href="#">Pavilion 4</a> , First Floor |   |   |   |  |   |  | <b>Poster<br/>Exhibition</b><br>09:00 – 17:00<br><b>First Floor</b><br><a href="#">Pavilion 5</a>                          |
| 12:00        | <b>PC-01</b><br>Do we need to<br>treat subthresh-<br>old ADHD?              |   |   |   |  |   |  |  |
| 13:00        |   |   |   |   |  |   |  | <b>Guided<br/>Poster Tours</b><br>12:45 – 14:15<br><b>P-15 to P-28</b><br><b>First Floor</b><br><a href="#">Pavilion 5</a> |
| 14:00        | Coffee Break  |   |   |   |  |   |  |  |
| 15:00        | <b>HT-17</b><br>Controversies on<br>AD trajectories                         | <b>HT-16</b><br>Adult ADHD<br>subtypes and<br>comorbid condi-<br>tions          | <b>YS-02</b><br>Young Scientists'<br>Session II               | <b>HT-18</b><br>ADHD beyond<br>the individual | <b>HT-19</b><br>Clinical<br>experience and<br>research find-<br>ings from the<br>Iberic peninsula<br>on ADHD | <b>HT-20</b><br>Tribute to our<br>WFADHD medal<br>recipient |  |  |
| 16:00        |   |   |   |   |  |   |  |  |
| 17:00        |   | <b>ES-05</b><br>ADHD and prob-<br>lematic internet<br>use: Treatment<br>options | <b>ES-04</b><br>Recommend-<br>ations for therapy<br>in school |   |  | <b>ME-06</b><br>ADHD and food                               | <b>ME-04</b><br>High severity pa-<br>tients with adult<br>ADHD |  |
| 18:00        |   |   |   |   |  |   |  |  |
| 18:45        |   |   |   |   |  |   |  |  |

## ADDITIONAL SESSION ROOMS

16:15 – 17:15

|           |              |  |
|-----------|--------------|--|
| Room 1.02 | <b>ES-06</b> | Treatment of ADHD and substance abuse                          |
| Room 1.04 | <b>ME-05</b> | Evidence for treatment of ADHD with psychostimulant medication |



# PROGRAMME OVERVIEW

Sunday, 28 April 2019

| Room<br>Time | AUD I  | Ground Floor<br>Foyer C              | First Floor<br>Pavilion 4                        |
|--------------|--|--------------------------------------|--|
| 08:30        |  | <b>Registration</b><br>08:00 – 13:00 | <b>Technical<br/>Exhibition</b><br>09:00 – 13:30 |
| 09:00        | <b>PL-03</b><br>Update on treat-<br>ment of ADHD<br>over the life-span |                                      | <b>Poster<br/>Exhibition</b><br>09:00 – 13:30    |
| 10:00        |  |                                      |  |
| 11:00        | Coffee Break/<br>Late Breaking News in <u>Pavilion 4</u> , First Floor |                                      |  |
| 12:00        | <b>PL-04</b><br>Future directions<br>in ADHD                           |                                      |  |
| 13:00        |  |                                      |  |
| 13:30        | <b>Closing<br/>Ceremony</b>  |                                      |  |
| 17:30        |  |                                      |  |



## CME CREDITS

The 7<sup>th</sup> World Congress on ADHD, Lisbon, Portugal, 25 – 28 April 2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **20 European CME credits** (ECMEC®s).

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at

**[www.ama-assn.org/education/earn-credit-participation-international-activities](http://www.ama-assn.org/education/earn-credit-participation-international-activities).**

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

## EACCME® credits

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form.

## Breakdown of ECMEC®s per day:

25 April 2019 ▶ **3 credits**  
 26 April 2019 ▶ **6 credits**  
 27 April 2019 ▶ **7 credits**  
 28 April 2019 ▶ **4 credits**



# SCIENTIFIC PROGRAMME

Thursday, 25 April 2019

## HT-01 Hot Topic Symposium

**14:00–15:30 Auditorium II**

### What sleep have to do with ADHD and its treatment?

Chairs: S. Kooij, The Netherlands  
M. Stein, USA

HT-01-001 The complex interface between ADHD and sleep  
M. D. Weiss, USA

HT-01-002 What we know about ADHD treatments and sleep problems?  
M. Stein, USA

HT-01-003 Sleep rhythm and adult ADHD  
S. Kooij, The Netherlands

HT-01-004 New research developments that can impact practice  
E. Sciberras, Australia

## HT-02 Hot Topic Symposium

**14:00–15:30 Room 5 B**

### Seeing beyond the disorder

Chairs: A. Bilbow, United Kingdom  
J. Sedgwick, United Kingdom

HT-02-001 The need for, the role of, and the impact of psychoeducation as seen through the work of a patient advocacy organisation in the community  
A. Bilbow, United Kingdom

HT-02-002 The good side of living with ADHD: The patient perspective  
I. Kestelman, Brazil

HT-02-003 A qualitative investigation of successful people with ADHD  
J. Sedgwick, United Kingdom

## HT-03 Hot Topic Symposium

**14:00–15:30 Room 5 C**

### Adult ADHD across Europe/World

Chairs: A. Ponte, Portugal  
P. Asherson, United Kingdom

HT-03-001 Europe  
P. Asherson, United Kingdom

HT-03-002 America  
J. Biederman, USA

HT-03-003 Asia  
T. Saito, Japan

HT-03-004 Africa  
R. Shoeman, South Africa

HT-03-005 South America  
P. Mattos, Brazil

## HT-04 Hot Topic Symposium

**14:00–15:30 Auditorium I**

### New perspectives on functional outcomes in children and adults with ADHD

Chairs: D. Coghill, Australia  
A. Philipsen, Germany

HT-04-001 Developmental changes of neuropsychological function from childhood to young adulthood in individuals with and without ADHD  
S. Gau, Taiwan

HT-04-002 Standardized assessment of functioning in ADHD using the International Classification of Functioning, disability and health (ICF) framework  
S. Bölte, Sweden

HT-04-003 Quality of life – short and long-term effects of multimodal treatment in adult ADHD  
A. Philipsen, Germany

HT-04-004 Decision making in ADHD  
D. Coghill, Australia

## HT-05 Hot Topic Symposium

**14:00–15:30 Room 5 A**

### Preterm birth and ADHD

Chairs: J. Kuntsi, United Kingdom  
L. A. Rohde, Brazil

HT-05-001 A risk score based on neonatal data to predict ADHD in pre-schoolers: Generating data in a clinical sample of preterm infants and validating it in population samples  
L. A. Rohde, Brazil

HT-05-002 ADHD and autism spectrum disorder symptoms in school-age children born preterm  
T. Bröring-Starre, The Netherlands

HT-05-003 Association of preterm birth with cognitive-neurophysiological impairments and ADHD symptoms: A sibling study of adolescents  
J. Kuntsi, United Kingdom

HT-05-004 Preterm birth and neuropsychiatric genetic risks: Investigating their interplay in a UK neonatal cohort  
A. Thapar, United Kingdom

# SCIENTIFIC PROGRAMME

Thursday, 25 April 2017

| RC-01  | Research Consortia Symposium  |
|--|---|
| <b>14:00–15:30</b>   | <b>Auditorium IV</b>  |
| <b>International collaboration on ADHD and substance abuse: New research on ADHD and substance abuse</b> |   |
| Chairs:  | C. Crunelle, Belgium<br>G. van de Glind, The Netherlands  |
| RC-02-001  | International consensus statement on diagnosis and treatment of ADHD in patients with substance use disorders<br>C. Crunelle, Belgium |
| RC-02-002  | Adult ADHD and its association with substance use and substance use disorders in young men<br>M. Mohler-Kuo, Switzerland              |
| RC-02-003  | Diagnosis of substance use disorders and the severity of substance use disorders in patients with and without ADHD<br>R. Ick, France  |
| RC-02-004  | Antisocial personality disorder in patients with substance abuse disorders with and without ADHD<br>G. van de Glind, The Netherlands  |

| YS-01              | Young Scientist' Session I  |
|--------------------|---|
| <b>14:00–15:30</b> | <b>Auditorium III</b>   |
| Chairs:            | S. Faraone, USA<br>P. Riederer, Germany   |
| YS-01-001          | Genes and brain cell types linked with selective neuronal vulnerability in ADHD<br>J. Hess, USA   |
| YS-01-002          | Genetic liability to ADHD and substance use disorders in individuals with ADHD<br>T. Wimberley, Denmark   |
| YS-01-003          | Genetic alteration of CADM1 is associated with ADHD during early life: An exploratory study with genetic, neuroimaging and animal model methods<br>J. Jin, People's Republic of China |
| YS-01-004          | Effects of methylphenidate on sleep in children with ADHD<br>I. Ferreira, Portugal  |

**15:30 – 16:00** **Coffee Break**

| RC-02   | Research Consortia Symposium   |
|---|--|
| <b>16:00–17:30</b>  | <b>Auditorium III</b>  |
| <b>EU consortia CoCA and Eat2BeNICE: The influence of food and/or physical activity on the course of ADHD</b> |  |
| Chairs:   | M. Ribases, Spain<br>N. Rommelse, The Netherlands  |
| RC-03-001   | A lifespan perspectives on the genetics of ADHD<br>M. Ribases, Spain                                       |
| RC-03-002   | ADHD and obesity: What do genetics tell us and how is the brain involved?<br>N. Roth Mota, The Netherlands |
| RC-03-003   | The effect of exercise on ADHD<br>S. Kittel-Schneider, Germany   |
| RC-03-004   | Food and ADHD on restriction diets, supplements, and probiotics<br>N. Rommelse, The Netherlands            |

| RC-03   | Research Consortia Symposium   |
|---|--|
| <b>16:00–17:30</b>  | <b>Room 5 A</b>  |
| <b>ADHD and its comorbidity with psychiatric and non-psychiatric disorders across the lifespan (EU Consortium CoCA)</b> |  |
| Chairs:   | A. Reif, Germany<br>S. Faraone, USA  |
| RC-01-001   | Polygenic risk for ADHD and association with outcomes<br>S. Dalsgaard, Denmark |
| RC-01-002   | ADHD and comorbidities: Gender differences<br>K. Klungsøyr, Norway             |
| RC-01-003   | Data mining in prediction models of obesity in ADHD<br>S. Faraone, USA         |
| RC-01-004   | ADHD and comorbidities: Cost analyses<br>A. Reif, Germany                      |

| HT-06  | Hot Topic Symposium                           |
|--|---|
| <b>16:00–17:30</b>   | <b>Room 5 B</b>                               |
| <b>Why guidelines give different directions for clinicians on the care and management of ADHD across the life cycle?</b> |   |
| Chairs:  | D. Coghill, Australia<br>J. Boavida, Portugal |
| HT-06-001  | The CADDRA perspective<br>D. Quinn, Canada    |

# SCIENTIFIC PROGRAMME

Thursday, 25 April 2019

- HT-06-002 The German perspective  
T. Banaschewski, Germany
- HT-06-003 The Australian perspective  
D. Coghill, Australia
- HT-06-004 The NICE perspective  
P. Asherson, United Kingdom

- HT-08-002 New perspectives on diet and other non-pharmacological interventions  
J. K. Buitelaar, The Netherlands  
T. Pringsheim
- HT-08-003 The burden of ADHD in older adults  
S. Kooij, The Netherlands

## HT-07 Hot Topic Symposium

16:00–17:30 Auditorium II

### ADHD and problematic internet use

Chairs: S. Chamberlain, United Kingdom  
S. Walitza, Switzerland

- HT-07-001 Association of digital media use with subsequent symptoms of ADHD among adolescents  
S. Lee, USA
- HT-07-002 The association between ADHD and internet addiction: A systematic review and meta-analysis  
L. Zheng-Tao, USA
- HT-07-003 Treatment of ADHD associated with pathological internet use  
S. Walitza, Switzerland
- HT-07-004 Cognition in ADHD and problematic internet use: Towards latent phenotype  
S. Chamberlain, United Kingdom

## HT-08 Hot Topic Symposium

16:00–17:30 Auditorium I

### Hot-topics for the clinicians

Chairs: J. K. Buitelaar, The Netherlands  
S. Kooij, The Netherlands

- HT-08-001 Association between epilepsy and ADHD  
I. Brikell, Sweden

## HT-09 Hot Topic Symposium

16:00–17:30 Room 5 C

### Attention deficits in ADHD: Assessment strategies for the clinic

Chairs: I. Manor, Israel  
O. Tucha, The Netherlands

- HT-09-001 Expert consensus on the composition of a neuropsychological assessment battery  
O. Tucha, The Netherlands
- HT-09-002 Subjective versus objective assessment strategies  
A. B. M. Fuermaier, The Netherlands
- HT-09-003 Clinical utility of continuous performances tests in the assessment of children and adults with ADHD  
I. Manor, Israel
- HT-09-004 Screening of attention deficits in adult ADHD  
S. V. Tourjman, Canada

## Opening Ceremony

19:30–20:30 Auditorium I

## Networking Reception

20:30–21:30 Auditorium I

## OPENING CEREMONY

19:30 | Auditorium I

- ➔ **Welcome Address** by the Congress President  
Luis A. Rohde, Brazil
- ➔ **Welcome Address** by the Chair of the Local Organizing Committee José Boavida, Portugal
- ➔ **Opening lecture**  
Andreas Meyer-Lindenberg, Germany  
Gene-Environment interactions and risk and resilience for mental disorders

- ➔ **Handover of the medal**  
of World Federation of ADHD  
to Yufeng Wang, People's Republic of China
- ➔ **Performance by 'Sous do Lena'**  
Cultural group of traditional Portuguese music

At the end of the Opening ceremony all participants are invited to join the Networking Reception in the exhibition area Hall 4.



# SCIENTIFIC PROGRAMME

Friday, 26 April 2019

## PL-01 Plenary Session

**08:30–10:30 Auditorium I**

### Long-term benefits and potential risks of medical treatments for ADHD

Chairs: J. K. Buitelaar, The Netherlands  
A. Warnke, Germany

**PL-01-001** ADHD medication and health related outcomes in the Hong Kong medical registers  
I. Wong, Hong Kong

**PL-01-002** ADHD medication and health-related problems in the Swedish medical registers  
H. Larsson, Sweden

**PL-01-003** Safety of drugs used in the treatment of ADHD during pregnancy and lactation  
A. Ornoy, Israel

**PL-01-004** What is lacking for longitudinal studies to be really informative on the ADHD long-term outcomes?  
J. Swanson, USA

**10:30 – 11:00 Coffee Break**

## LN-01 Late Breaking News

**10:30–11:00 Pavilion 4**

Chairs: A. Caye, Brazil  
K. Ellison, USA

**LN-01-001** Individual differences versus the average patient: Mapping the heterogeneity in ADHD using normative models  
J. K. Buitelaar, The Netherlands

*(Supported by an unrestricted grant from MEDICE)*

## RT-01 Round Table

**11:00–12:30 Auditorium I**

### Grand-round: Managing ADHD in pre-scholars

Presenter: G. Polanczyk, Brazil  
Discussants: M. Danckaerts, Belgium  
E. Sonuga-Barke, United Kingdom

## P-01 Guided Poster Tour

**14:30–16:00 Pavilion 5**

### Aetiology

Chair: S. Faraone, USA

**P-01-001** Traumatic stress during pregnancy caused by a natural disaster and the risk of ADHD in children: The case of Aila Cyclone  
T. Hanc, Poland  
R. Chakraborty, S. Koziel

**P-01-002** Predicting ADHD symptoms outcomes at 5 years of age: Findings from birth cohort study  
R. Nakahara, Japan  
T. Nishimura, K. J. Tsuchiya

**P-01-003** Circadian gene expression in human dermal fibroblasts is altered by different synchronization methods  
D. Palm, Germany  
A. Uzoni, J. Thome, F. Faltraco

**P-01-004** Hypothalamic- pituitary-adrenal axis' activity in ADHD patients  
A. Alvim-Soares, Brazil  
P. Pereira, D. Souza-Costa, G. Chequer, D. Rosa, C. Santan, T. Elcurry Silva, E. Sacramento, M. Romano-Silva, D. Miranda

**P-01-005** ADHD and early childhood residential care: A study case about the consequences of the first years' lack of affect  
R. Lineros Linero, Spain  
C. Garcia Ribeiro, L. Martín García, J. Lull Carmona, J. J. Ortiz Guerra

**P-01-006** Sub-clinical Iodine deficiency: An important player in ADHD  
A. F. Sá Carneiro, Portugal  
S. Norberto, V. Cruz Fernandes, M. Luz Maia, E. Pinto, D. Pestana, A. Almeida, O. Queirós, R. Coelho, C. Calhau, M. Figueiredo-Braga

**P-01-007** Neurophysiological treatment of primitive preborn reflexes and their importance to child and adolescent psychiatry  
R. Meyers, Germany

# SCIENTIFIC PROGRAMME

Friday, 26 April 2019

| P-02               | Guided Poster Tour   |
|--------------------|--|
| <b>14:30–16:00</b> | <b>Pavilion 5</b>  |
| <b>Genetics</b>    |  |
| Chair:             | B. Franke, The Netherlands   |
| P-02-001           | Genotyping of DRD4 and DAT1 genes may differentiate symptoms of ADHD and sluggish cognitive tempo<br>H. Bolat, Turkey<br>G. Ünsel Bolat, E. S. Ercan, A. Tahillioglu, K. U. Yazici, A. Bacanlı, E. Pariltay, D. Aygunes, B. Kosova, L. A. Rohde, H. Akin |
| P-02-003           | ADHD polygenic risk and migraine<br>M. Debst, Denmark<br>E. Agerbo, P. B. Mortensen, S. Dalsgaard, I. Brikell  |
| P-02-004           | Describing the genetic architecture of ADHD using linked-read sequencing: A case-control study from the isolated population of the Faroe Islands<br>N. O. Gregersen, Faroe Islands<br>J. F. Zachariasen  |
| P-02-005           | Family and case-control association study of the FKBP5 stress related gene with ADHD following by meta-analysis<br>E. Grünblatt, Switzerland<br>A. M. Werling, S. Walitza  |
| P-02-006           | Peripheral mitochondria DNA copy numbers are increased in Korean ADHD<br>B.-N. Kim, Republic of Korea<br>C.-M. Yang, J. Lee, I.-H. Kim   |
| P-02-007           | The relationship among ADHD polygenic risk scores, stressful life events, and ADHD symptoms in healthy adults<br>T. Li, The Netherlands<br>N. Mota, A. Arias Vasquez, B. Franke  |
| P-02-008           | Family-based association study on functional alpha-synuclein polymorphisms in ADHD<br>T. Renner, Germany<br>M. Sharma, M. Romanos, K.-P. Lesch, S. Walitza, A. Conzelmann, R. Krüger, M. Gerlach   |
| P-02-009           | Shared genetic risk between verbal and visual spatial working memory deficiency of ADHD<br>Y. Zhong, People's Republic of China<br>W. Chen, S. Chang, L. Sun, Y. Wang, L. Yang   |
| P-02-010           | Role of glutamic acid decarboxylase (GAD1) gene polymorphisms (Rs 3749034 and Rs11542313) in susceptibility to ADHD: An Egyptian study<br>M. Seleem, Egypt<br>H. Rady, S. Hammouda, M. Eid   |

| P-03                | Guided Poster Tour   |
|---------------------|--|
| <b>14:30–16:00</b>  | <b>Pavilion 5</b>  |
| <b>Epidemiology</b> |  |
| Chair:              | K.-P. Lesch, Germany   |
| P-03-001            | Stagnated prevalence of diagnosis and medication for ADHD in Korean youth<br>G.-H. Bahn, Republic of Korea<br>S.-Y. Lee, M.-H. Hong  |
| P-03-002            | Cessation of cohabitation during pregnancy and offspring ADHD<br>K. Bang Madsen, Denmark<br>L. Lund, L. Hohwü  |
| P-03-003            | Application of Conners' Rating Scale on children and teenagers assessed in an ambulatory of academic underachievement<br>M. A. da Silva Cristovam, Brazil<br>C. R. Lopes, V. Camargo, J. B. Costa, L. E. Souza, M. F. Rodoy Bertol, D. A. Pielak, M. K. Lima, T. D. Oliveira, M. R. Clivatti |
| P-03-004            | ADHD and comorbid eating disorders in a Spanish sample of female adolescents<br>A. Díez Suárez, Spain<br>I. Martínez Gárate, M. Vallejo, P. de Castro Manglano, C. Soutullo Esperon  |
| P-03-005            | High prevalence of ADHD for Korean adolescent inmates<br>H.-S. Roh, Republic of Korea<br>B.-S. Kim, Y.-S. Lee, H.-C. Hwang   |
| P-03-006            | Suggestive symptoms of ADHD in a sample of adult patients diagnosed with eating disorders<br>M. Ruiz, Spain<br>A. Cano, C. Campos, M. T. Iglesias, R. Martín   |
| P-03-007            | Early detection of mental and behavioral disorders of young children: A nationwide population-based pilot study in Russia (data 2017)<br>N. Simashkova, Russia<br>M. Ivanov, G. Kozlovskaya, E. Makushkin  |
| P-03-008            | Exposure to air pollution in early childhood and the association with ADHD<br>M. Thygesen, Denmark<br>G. J. Holst, B. Hansen, J. Brandt, C. Geels, A. Kalkbrenner, D. Schendel, C. B. Pedersen, S. Dalsgaard   |
| P-03-009            | Predictors of ADHD symptoms in childhood and adolescence over time: Results of the longitudinal BELLA study<br>A. Wuestner, Germany<br>C. Otto, R. Schlack, H. Hölling, F. Klasen, U. Ravens-Sieberger   |

- P-03-010** Identifying executive functioning profiles of pre-schoolers with ADHD: A multi-method approach  
P. Graziano, USA  
T. Landis, A. Garcia
- P-03-011** Differences in emotional dysregulation and well-being among German and Latin American adults with ADHD  
K. Bauer, Germany
- P-03-012** ADHD in acute care child and adolescent psychiatric inpatients  
L. Martin Garcia, Spain  
J. Lull Carmona, R. Lineros Linero, C. Garcia Ribeiro, J. J. Ortiz
- P-03-013** Tunisian military children with ADHD  
I. Soualmia, Tunisia  
H. Slama
- P-03-014** Implementation of New Forest Parenting Programme (NFPP) in Uganda  
R. Mpango, Uganda

|             |                           |
|-------------|---------------------------|
| <b>P-04</b> | <b>Guided Poster Tour</b> |
|-------------|---------------------------|

**14:30–16:00**

**Pavilion 5**

**Diagnosis – adults**

Chair: F. Reimherr, USA

- P-04-001** Multicenter application of diva-5, Korean version, for adults with ADHD  
G.-H. Bahn, Republic of Korea  
S.-Y. Lee, M.-H. Hong, D.-H. Han, Y.-S. Lee, B.-S. Kim, S.-Y. Bhang, E.-J. Kim, S.-Y. Lee, Y.-S. Joung, H. Yoo
- P-04-002** Five to fifteen questionnaires used as a retrospective assessment of childhood symptoms in the context of adult assessment  
J. Borg, Sweden  
J. Jokinen, S. Lajic, E. Renhorn, A. Trillingsgaard, B. Kadesjö, C. Gillberg, T. Hirvikoski
- P-04-003** Nine everyday situations, nine different forms of attention  
Y. Groen, The Netherlands  
A. B. Fuermaier, L. Tucha, M. Weisbrod, S. Aschenbrenner, O. Tucha
- P-04-004** The validity reliability and Turkish transliterational equivalence study of excessively mind wandering scale  
S. Gunay Aksoy, Turkey  
U. M. Aksoy, A. E. Tufan, H. Duzcu, B. Semerci

- P-04-005** Discriminating ADHD from healthy controls using functional connectivities: The cross-sectional classification and the longitudinal prediction  
X. Guo, People's Republic of China  
D. Yao, Q. Cao, Q. Zhao, H. Li, F. Huang, Y. Wang, L. Liu, Q. Qian, Y. Wang, J. Sui, L. Sun
- P-04-006** Attitudes towards adults with ADHD in a Norwegian sample  
R. Kenter, Norway  
E. Nordby, A. G. Parnemann, A. J. Lundervold
- P-04-007** The characteristic of attentional networks in sluggish cognitive tempo  
K. Kim, Republic of Korea  
J.-H. Lee
- P-04-008** Distinct classification of adult ADHD: A latent class analysis of ADHD symptom profile  
Y.-H. Oh, Republic of Korea  
J.-H. Baek
- P-04-009** Persistent ADHD vs adult ADHD, so different from each other? The importance of sex and executive functions in a clinical sample (PROMETEO program)  
L. Palacios Cruz, Mexico  
A. Arias-Caballero De Miguel, E. M. Cárdenas Godínez, R. E. Ulloa Flores, K. Garza Gallegos, M. d. Carmen Lara Muñoz, A. Frago, F. Galicia- Moreno, R. Aguerre Estevez, P. Mayer-Villa, M. Rosetti
- P-04-010** Case report: ADHD in adulthood as a differential diagnosis of therapy-refractory major depressive disorder  
J. Unterholzner, Austria  
A. Naderi-Heiden, N. Praschak-Rieder, S. Kasper, T. Vanicek
- P-04-011** Static and dynamic functional brain connectivity based single-subject classification of ADHD  
Y. Zhong, People's Republic of China  
Y. Sun, Q. Cao, L. Sun, Y. Wang, Z. Yang, L. Yang
- P-04-012** Prevalence and impact of under- or misdiagnosed ADHD in adults referred for the treatment of mood and anxiety disorders  
T. Sternat, Canada  
K. Fotinos, S. Lokuge, E. Sherifi, I. Epstien, M. Katzman, P. M. Wehmeier, Germany, J. Wolff, N. Cabanas, M. Bender

# SCIENTIFIC PROGRAMME

Friday, 26 April 2019

- P-04-013 ADHD core symptom assessment in adults with ADHD compared to adults with ADHD and comorbid Borderline Personality Disorder using a computer-based Continuous Performance Test (cb-CPT) combined with an infra-red motion-tracking device  
P. M. Wehmeier, Germany  
J. Wolff, N. Cabanas, M. Bender

## P-05 Guided Poster Tour

14:30–16:00 **Pavilion 5**

### Diagnosis – children and adolescents

Chair: M. Romanos, Germany

- P-05-001 The efficacy of cognitive assessments in distinguishing between ADHD, non-ADHD and SCT  
L. Abdool Gafoor, South Africa  
A. Burke, J. Fourie
- P-05-002 Educational tool ADHDMENTE: Diagnostic indicator application ADHD in children and teenagers  
C. Aparecido de Araújo Afonso, Brazil  
R. Monteiro Azzi dos Santos, L. Uriel da Silva Lima
- P-05-003 The possibility of virtual reality as an ADHD screening tool  
S.-M. Bae, Republic of Korea  
S.-K. Lee, S. Lee, S.-J. Cho
- P-05-004 The CPT-3 versus the QB-test: A task-oriented computerized assessment of attention-related problems in out-patient children: Will diagnosis predict the atypical attention scores?  
L. R. Kvitland, Norway  
K. Jakobsen, H. Achkhan, T. Berg, N. R. Dahlen, G. M. Kirkholt, K. N. Koren, M. F. Næss
- P-05-005 The ATENTO Project or how to assess executive function in ADHD cases during school age  
T. Luque, Spain  
F. Sánchez-Sánchez
- P-05-006 A new instrument to assess executive function in ADHD during school age  
T. Luque, Spain  
F. Sánchez-Sánchez
- P-05-007 A new approach in diagnostics and therapy on ADHD  
R. Meyers, Germany
- P-05-008 Predictors and outcomes of ADHD in (pre) scholar child  
M. Pereira Antunes, Portugal  
A. F. Lopes, M. Falcão, M. Liz, P. Magalhães, G. Fernandes

- P-05-009 A novel approach to measuring attention in youth with ADHD  
J. Pylypow, Canada  
L. Balbuena, D. Quinn
- P-05-010 The influence of sluggish cognitive tempo on child self-report measures in children with ADHD  
B. V. Saez, Spain  
M. Servera, C. Trias
- P-05-011 The distinguishing characteristics of pure sluggish cognitive tempo from ADHD with and without sluggish cognitive tempo in an epidemiological sample  
A. Tahillioglu, Turkey  
N. Dogan, G. U. Bolat, E. S. Ercan
- P-05-012 A deep learning based approach for missing data imputation in Attention Deficit Hyperactivity Disorder (ADHD)  
C.-Y. Cheng, Taiwan  
S.-F. Gau

## P-06 Guided Poster Tour

14:30–16:00 **Pavilion 5**

### Comorbidity – adults

Chair: W. Retz, Germany

- P-06-001 ADHD symptomatology and sleep disorders in a Romanian sample of patients with chronic psychoactive substance abuse  
A. M. Buica, Romania  
E. Andrei, A. Irimie-Ana, F. Rad, I. Dobrescu
- P-06-002 A retrospective hospital center study - ADHD in childhood and bipolar affective disorder: Is there a relationship?  
A. Costa, Portugal  
A. Samico, S. Melo, A. Venâncio, G. Mendes
- P-06-003 Avoidance-related distress in patients with PTSD and ADHD  
M. Katzman, Canada  
E. Sherifi, K. Fotinos, S. Lokuge, T. Sternat, I. Epstein
- P-06-004 The association between insomnia and alcohol consumption in adults with ADHD  
A. J. Lundervold, Norway  
A. Halmøy, D. A. Jensen, J. Haavik
- P-06-005 Childhood psychological traumatization is associated with prevalent comorbid psychiatric disorders and current PTSD in adult patients with ADHD  
D. E. Peleikis, Norway  
M. Fredriksen



- P-06-006** **ADHD: Shall we sleep on it?**  
D. Pereira, Portugal  
M. Moreno, F. Vien, A. Ponte, T. Teodoro, M. Mendes, F. Gonçalves
- P-06-007** **Suicide: A primary or secondary road in ADHD – clinical case**  
D. Pereira, Portugal  
M. Moreno, F. Vien, A. Ponte, T. Teodoro, M. Mendes, F. Gonçalves
- P-06-008** **ADHD is associated with a pervasive pattern of risky behavior which mediated by benefit perception**  
R. Shoham, Israel  
E. Sonuga-Barke, I. Yaniv, Y. Pollak
- P-06-009** **Examining the role of chronic anhedonia as a transdiagnostic risk factor for ADHD, treatment-resistance, and suicidal behavior in patients with generalized anxiety disorder**  
T. Sternat, Canada  
K. Fotinos, S. Lokuge, E. Sherifi, I. Epstein, M. Katzman
- P-06-010** **ADHD and Borderline Personality Disorder: Comorbidity or common underlying disease process**  
T. Teodoro, Portugal  
D. Pereira, A. Ponte, M. Moreno, F. Vian, R. Durval
- P-06-011** **Clinical validity for home based on-line testing of objective markers associated with ADHD**  
F. Ulberstad, Sweden  
M.-L. Chavanon, H. Boström, H. Christiansen, M. Knollman, J. Wiley, L. B. Thorell

- P-07-003** **The prevalence of psychiatric comorbidity in children and adolescents with ADHD in Turkey**  
M. Ipci, Turkey  
S. B. Inci Izmir, H. Türkçapar, U. Akyol Ardic, E. S. Ercan
- P-07-004** **Attention deficit/hyperactivity symptoms are affecting mathematics achievement and well-being in students with mild intellectual disabilities**  
E. Kiive, Estonia  
T. Kivirähk
- P-07-005** **Sluggish cognitive tempo but not ADHD symptoms predict child body mass index: Examination in a sample of clinically referred youth**  
D. Sarver, USA  
A. Cox, A. Cash
- P-07-006** **Association between dyslexia/high functioning autism symptoms and sluggish cognitive tempo symptoms in the patients who applied to a child psychiatry outpatient clinic**  
A. Tahillioglu, Turkey  
A. Satar, D. Celik, S. Huseynova, E. S. Ercan
- P-07-007** **Differences in ADHD psychiatric comorbidities in childhood and adulthood**  
F. Vian, Portugal  
D. Pereira, M. Moreno
- P-07-008** **Co-existing psychiatric disorders associated with ADHD: New findings of comorbidity in a clinically referred sample of children and adolescents with recently diagnosed ADHD**  
S. Walitza, Switzerland  
A. M. Werling, R. Drechsler
- P-07-009** **Symptoms overlap in ADHD and bipolar disorder in paediatric population: An overlooked issue?**  
K. M. Wilczynski, Poland  
L. Cichon, I. Jelonek, M. Janas-Kozik
- P-07-010** **Characteristics of callous-unemotional traits in Chinese preschool children with ADHD**  
J. Zhang, People's Republic of China  
W. Li
- P-07-011** **Attention deficit hyperactivity symptoms and sleep habits among pre-schoolers: Is there a relationship?**  
R. Gomes, Portugal  
B. Sousa, D. Gonzaga, M. Rios, C. Prior, I. Vaz Matos

| P-07  | Guided Poster Tour  |
|---|---|
| <b>14:30–16:00</b>                            |   |
| <b>Pavilion 5</b>                             |   |
| <b>Comorbidity – children and adolescents</b> |   |
| Chair: S. Walitza, Switzerland                |   |
| <b>P-07-001</b>                               | <b>Emotion regulation difficulties in adolescents with ADHD and/or dyslexia</b><br>L. Battistutta, Luxembourg<br>G. Steffgen  |
| <b>P-07-002</b>                               | <b>Do weight, waist circumference and fat tissue content indicate increased risk of obesity in children with ADHD?</b><br>E. Bryl, Poland<br>T. Hanc, P. Mamrot, M. Dmitrzak-Weglarz, A. Dutkiewicz, A. Slopian |

# SCIENTIFIC PROGRAMME

Friday, 26 April 2019

| P-08               | Guided Poster Tour   |
|--------------------|--|
| <b>14:30–16:00</b> | <b>Pavilion 5</b>  |
|                    | <b>Autism spectrum disorder</b>  |
| Chair:             | C. Freitag, Germany  |
| P-08-001           | Role of school bullying involvement in depression, anxiety, suicidality, and low self-esteem among adolescents with high-functioning autism spectrum disorder<br>W.-J. Chou, Taiwan  |
| P-08-002           | ADOS-2 scores in adults with ADHD with or without autism spectrum disorder<br>W. Hayashi, Japan<br>Y. Hanawa, K. Aoyagi, I. Yuriko, D. Nakamura, A. Iwanami  |
| P-08-003           | Cognitive switching processes, sustained attention and interference control in children with and without ADHD symptoms<br>P. Mamrot, Poland<br>T. Hanc, E. Bryl, M. Dmitrzak-Weglarz, A. Dutkiewicz, A. Slopian  |
| P-08-004           | Are ADHD and autism spectrum disorder dissociating or overlapping disorders? Occulomotor evidence from multiple tasks<br>D. Seernani, Germany<br>K. Damania, C. Ioannou, H. Hill, N. Anderson, T. Foulsham, G. Boccignone, W. Bischof, M. Biscaldi, U. Ebner-Priemer, C. Klein |
| P-08-005           | The systematic review and meta-analysis of literature on deficits in oxytocynergic and vasopresynergic systems in course of autism spectrum disorder<br>K. M. Wilczynski, Poland<br>M. Janas-Kozik   |
| P-08-006           | ADHD/autism spectrum disorder traits and exposure to pesticides: A systematic review<br>L. Tessari, Italy<br>M. Angriman, A. Conca, S. Cortese   |
| P-08-007           | Shared and distinct executive function profiles between ADHD and autism spectrum disorder: A meta-analysis<br>R. Xie, People's Republic of China<br>L. Yang  |
| P-08-008           | Neurocognitive variability in children with ADHD and autism spectrum disorder: exploring the motor coordination and planning function<br>M. Zhang, People's Republic of China<br>Y. Huang  |

| P-09               | Guided Poster Tour  |
|--------------------|---|
| <b>14:30–16:00</b> | <b>Pavilion 5</b>   |
|                    | <b>Substance use disorders</b>  |
| Chair:             | G. van de Glind, The Netherlands  |
| P-09-001           | Alcohol and drug use disorders among adults with ADHD: Associations with ADHD symptom severity and emotional dysregulation<br>E. Anker, Norway<br>J. Haavik, T. Heir  |
| P-09-002           | ADHD and substance use disorder: A literature review<br>M. Ferraz de Liz, Portugal<br>M. Lima Falcão, A. F. Lopes   |
| P-09-003           | Journey from ADHD to OCD<br>L. Macias, USA<br>R. Macias   |
| P-09-004           | Getting psychotic while looking for tranquillity: Two sides of cocaine consumption in adult ADHD – a case report<br>N. Ribeiro, Portugal<br>A. M. Franco, I. Fonseca, P. A. Afonso, M. M. Magalhães, L. Moreno, S. Penedos, M. J. Freire, J. Nogueira, J. Vieira, R. Ribeiro, A. Gamito |
| P-09-005           | Cigarette smoking severity among adults in Substance Use Disorder treatment by ADHD status: Results from ICASA studies<br>N. C. Sánchez-García, Puerto Rico<br>M. Velez-Pastrana, R. González   |
| P-09-006           | Comorbid psychiatric disorders and executive functioning of Latino male prisoners with ADHD and substance use disorders<br>M. Velez-Pastrana, Puerto Rico<br>R. Gonzalez  |

| P-10               | Guided Poster Tour   |
|--------------------|--|
| <b>14:30–16:00</b> | <b>Pavilion 5</b>  |
|                    | <b>Electrophysiology</b>   |
| Chair:             | A. Warnke, Germany   |
| P-10-001           | Effects of short-term alpha-rhythm neurofeedback on Go/NoGo performance in adult ADHD: A controlled EEG study<br>M.-P. Deiber, Switzerland<br>J. Colin, R. Hasler, V. Giacomini, A. Dayer, J.-M. Aubry, T. Ros, N. Perroud |
| P-10-002           | Sleepiness and cognitive performance in adults with ADHD: EEG slowing and observer-rated sleepiness<br>B. Helfer, United Kingdom<br>P. Asherson  |

- P-10-003** Beta-phase high gamma-amplitude coupling deficits in children with ADHD  
D. Ibañez Soria, Spain  
E. Kroupi, A. Rojas, M. Castellano, A. Soria Frisch, M. Servera, G. Garcia Banda
- P-10-004** Quantitative electroencephalography in hypersomnia patients with ADHD and narcolepsy patients without ADHD  
W. Ito, Japan  
H. Narisawa
- P-10-005** The neural correlations of spatial attention and working memory deficits in adults with ADHD  
X. Luo, People's Republic of China  
J. Guo, L. Liu, X. Zhao, D. Li, H. Li, Q. Zhao, Y. Wang, Q. Qian, Y. Wang, Y. Song, L. Sun
- P-10-006** Differences in neurophysiological characteristics according to the ADHD subtypes  
Y.-J. Park, Republic of Korea  
J.-Y. Park, K.-G. Jhung
- P-10-007** Electrodermal responses to the unfamiliar situation in children with ADHD and conduct problems symptoms  
J. Ratajczak, Poland  
T. Hanl
- P-10-008** Event-related brain oscillatory and ex-Gaussian markers of ADHD remission and persistence  
I. Vainieri, United Kingdom  
G. Michelini, N. Adamo, C. Cheung, P. Asherson, J. Kuntsi

|             |                           |
|-------------|---------------------------|
| <b>P-11</b> | <b>Guided Poster Tour</b> |
|-------------|---------------------------|

**14:30–16:00****Pavilion 5****Pathophysiology – adults**

- Chair: J. A. Sergeant, The Netherlands
- P-11-001** Basic processes as foundations of cognitive impairment in adult ADHD  
M. Butzbach, The Netherlands  
A. Fuermaier, S. Aschenbrenner, M. Weisbrod, L. Tucha, O. Tucha
- P-11-002** Comparison of voluntary and automatic orienting of attention in different age children with ADHD  
L. R. Carreiro, Brazil  
M. Martins de Castro Mari, V. Rocha Reis Lellis, R. Angulo Condoretti Barro, M. C. Triguero Veloz Teixeira

- P-11-003** Cognitive profile of a Brazilian adults' sample with complaints of inattention compatible with ADHD  
L. R. Carreiro, Brazil  
R. A. Condoretti Barro, M. Miyahara Moraes Silva, J. P. Pereira Werner da Silva, I. Trinta Paes
- P-11-004** Correlation of the hereditary characteristics between parents and children with ADHD through the virtual tools AULA® and AQUARIUM®  
J. C. García Beristain, Mexico  
E. Barragán Pérez, A. Saldivar Santillan
- P-11-005** What is the relation between attachment and ADHD? A theoretical review  
C. Garcia Ribeiro, Portugal  
R. Lineros Linero, L. Martín García, J. Lull Carmona, J. J. Ortiz Guerra
- P-11-006** Sex differences in the patterns of executive dysfunctions in adults with ADHD as compared to healthy adults  
Y.-J. Huang, Taiwan  
S. S.-Fen Gau, Y.-J. Lin
- P-11-007** Task switching in adult ADHD: Impairments due to attentional set shifting?  
J. Kerner auch Koerner, Germany  
A. Luna-Rodriguez, M. Wendt, C. Gawrilow, T. Jacobsen, H. Goossens-Merkt
- P-11-008** ADHD is linked to procrastination: Role of expectancy and impulsiveness  
R. Netzer Turgeman, Israel  
Y. Pollak
- P-11-009** Emotional dysregulation: A case of ADHD perceived as cyclothymic disorder on an adult patient  
J. Nogueira, Portugal  
M. Franco, N. Ribeiro, I. Fonseca, M. Freire, J. Vieira, P. Afonso, M. Magalhães, S. Penedos, L. Moreno, R. Ribeiro, A. Gamito, R. Costa, R. Durval
- P-11-010** ADHD characteristics in Brazilian adults: An online survey  
F. Meirelles Leite, Brazil  
M. Zimmer, V. Godoy, L. Ferreira

# SCIENTIFIC PROGRAMME

Friday, 26 April 2019

## P-12 Guided Poster Tour

14:30–16:00

Pavilion 5

### Pathophysiology – children and adolescents

Chair: T. Banaschewski, Germany

**P-12-001** The awareness project: Differences between children diagnosed with ADHD and healthy control children as to sleep difficulties and some behavioural aspects

K. Al-Otaibi, Saudi Arabia

S. Al-Otaibi, S. Al-Otaibi, H. Al-Dughaisheem, H. Al-Ammar

**P-12-002** Improved executive functioning but not ADHD symptoms in children with ADHD at 1-year follow-up

M. Hotakainen Dolan, Ireland

H. O'Reilly, H. Kiiski

**P-12-003** Sensory processing issues and assessment in children with ADHD

J. Keating, Ireland

R. Gaffney, J. Bramham, M. Downes

**P-12-004** Inhibition dysfunctions and working memory in children with ADHD: A pilot study

C. Lee, Hong Kong

**P-12-005** Stress biomarkers and cognition in adolescents with ADHD

M. Llorens Capdevila, Spain

M. Pamiás Massana, M. Barba Balleca, J. Torralbas Ortega, S. Pujol Serra, M. Betriu Sabate, L. Urraca Camps, L. Torrent Sola, A. Lorenzo Capilla, J. Labad Arias

**P-12-006** Evaluation of teacher ratings regarding emotional intelligence in primary school children with ADHD

A. Rodopman Arman, Turkey

A. Buyukdeniz

**P-12-007** ADHD in gifted children: A single case report

J. M. Sémelas Ledesma, Spain

A. Osuna Benavides

**P-12-008** Examining the neuropsychological functions and psychosocial problems in preschool ADHD: From the situational perspective

H.-G. Shouou Lian, Taiwan

**P-12-009** Inhibition in the Antisaccade task: An endophenotype for ADHD

M. Siqueiros Sanchez, Sweden

T. Falck-Ytter, D. Kennedy, S. Bölte, P. Lichtenstein, B. D'Onofrio, E. Pettersson

**P-12-010** Evaluation of joint attention abilities in children with ADHD: An eye tracking study

R. D. Temelturk, Turkey

B. Ustun Gullu, O. Aydin, B. G. Kilic

**P-12-011** Different behavioral and cognitive specificities in shared symptoms between ADHD, intellectual disability and dyslexia to guide differential diagnosis rationale

L. R. Carreiro, Brazil

R. Luisa de Freitas Marino, A. de Oliveira Souza, M. C. Triguero V. Teixeira, A. Gotuzo Seabra

**P-12-012** The Weiss Functional Impairment Rating Scale in a Norwegian clinical sample of adolescents with ADHD

A.-L. Juul Haugan, Norway

P. H. Thomsen, S. Lydersen, A. M. Sund, T. S. Nøvik

**P-12-013** Is eveningness preference associated with the presentation and severity of ADHD? Study in an adolescent clinical sample and high-risk siblings

E. Galicia, Mexico

A. Arias-Caballero, L. Palacios-Cruz

**P-12-014** Behaviors of children with ADHD that increase their risk to be bullied in school

A. Irimie-Ana, Romania

M.-V. Hatis, S. L. Mihai

**P-12-015** Reviewing peer functioning in school-aged girls with ADHD

F. Kok, The Netherlands

Y. Groen, A. B. M. Fuermaier, O. Tucha

## P-13 Guided Poster Tour

14:30–16:00

Pavilion 5

### Neuroimaging I

Chair: K. Rubia, United Kingdom

**P-13-001** Aberrant developmental neuroanatomical changes associated with ADHD symptoms changes: A longitudinal image study of youths with ADHD

Y.-C. Chen, Taiwan

S. S.-Fen Gau

**P-13-002** Structural covariance in internet gaming disorder with comorbid ADHD

J.-W. Choi, Republic of Korea

B.-S. Jeong, D.-H. Kim, D.-H. Han



- |  |   |
|--|---|
| <p><b>P-13-003</b>     <b>Blunted opioid release after stimulant medication in adults with ADHD: A Carfentanil-PET study</b><br/>A. Colasanti, United Kingdom<br/>J. Meyers, B. Helfer, I. Mick, S. Lukito, P. Asherson, D. Nutt, A. Lingford-Hughes, I. Rabiner, K. Rubia</p> <p><b>P-13-004</b>     <b>Sluggish cognitive tempo symptoms in ADHD may be associated with occipital compensator mechanisms</b><br/>E. S. Ercan, Turkey<br/>B. Kardar, G. Ünsel Bolat, B. Baytunca, C. Calli</p> <p><b>P-13-005</b>     <b>Do hypo- and hyper-dopaminergic states simulate ADHD in healthy participants? Evidence from a pharmac-fMRI study</b><br/>O. Grimm, Germany<br/>K. Kuranel, L. Kvibäck, V. Kopfer, M. Kuhn, M. de Greck, M. Plichta, A. Reif</p> <p><b>P-13-006</b>     <b>Methylphenidate and atomoxetine normalise fronto-parietal activation in ADHD during sustained attention</b><br/>O. Kowalczyk, United Kingdom<br/>A. Cubillo, A. Smith, N. Barrett, V. Giampietro, M. Brammer, A. Simmons, K. Rubia</p> <p><b>P-13-007</b>     <b>Neurobiology of ADHD: The state of art</b><br/>A. Lopes, Portugal<br/>M. Liz, M. Falcão, M. Antunes, T. Correia</p> <p><b>P-13-008</b>     <b>Early sexual dimorphism in brain development trajectory among pre-schoolers with ADHD</b><br/>M. Mahone, USA<br/>L. Kalb, D. Crocetti, D.-Y. Song, S. Mostofsky, L. Jacobson</p> <p><b>P-13-009</b>     <b>Fronto-striatal glutamatergic dysregulation in adult patients with ADHD: A 1H-MR spectroscopy study</b><br/>P. Ohrmann, Germany<br/>J. Trieloff, A. Pedersen, L. Materna, J. Bauer</p> <p><b>P-13-010</b>     <b>Neural correlates of perspective-taking in adolescents: An fMRI study</b><br/>J.-W. Son, Republic of Korea<br/>S.-K. Park</p> | <p><b>P-14-002</b>     <b>Attentional lapses and ADHD: Amplitude variability over trials in hemodynamic responses in the posterior default mode network during Go/No-Go task performance</b><br/>L. Sorensen, Norway<br/>M. C. Stevens</p> <p><b>P-14-003</b>     <b>Alterations of cerebral perfusion and functional brain connectivity in medication-naïve male adults with ADHD</b><br/>Y. Tan, People's Republic of China<br/>L. Liu, Y.-F. Wang, H.-M. Li, M.-R. Pan, M.-J. Zhao, F. Huang, Y.-F. Wang, Y. He, Q.-J. Qian</p> <p><b>P-14-004</b>     <b>Prediction of ADHD based on subcortical brain regions and subdivisions of the hippocampus and amygdala</b><br/>T. Vanicek, Austria<br/>A. Kautzky, R. Seiger, G. S. Kranz, G. Gryglewski, A. Höflich, A. Hahn, S. Kasper, R. Lanzenberger</p> <p><b>P-14-005</b>     <b>Systematic overview of neuroanatomical differences in ADHD: Definitive evidence</b><br/>B. Vieira de Melo, Portugal</p> <p><b>P-14-006</b>     <b>Effect of atomoxetine hydrochloride on working memory in children with ADHD: A functional near-infrared spectroscopy study</b><br/>X. Wu, People's Republic of China<br/>S. Miao, Y. Gu, X. Wang, W. Song, X. Li, J. Yang</p> <p><b>P-14-007</b>     <b>ADHD traits in general population: White matter alterations and ADHD related polygenic risk</b><br/>Z. Wu, People's Republic of China<br/>M. Hoogman, J. Bralten, H. Lemaître, Q. Cao, L. An, L. Liu, L. Sun, B. Yang, G. Schumann, Y. Wang, B. Franke, L. Yang</p> <p><b>P-14-009</b>     <b>The comparison between abnormal brain MRI and normal brain MRI with anti-N-methyl-D-aspartate receptor encephalitis in children</b><br/>J. Yang, People's Republic of China<br/>X. Cui</p> |
|--|---|

|             |                           |
|-------------|---------------------------|
| <b>P-14</b> | <b>Guided Poster Tour</b> |
|-------------|---------------------------|

**14:30–16:00** **Pavilion 5**

**Neuroimaging II**

Chair: A. Fallgatter, Germany

- P-14-001**     **Structural brain characteristics and neuropsychological impairment in adult ADHD: Study protocol**  
H. C. Siemoneit, Germany  
I. Kuchler, P. Tonn

**15:00 – 15:30**

**Coffee Break**

# SCIENTIFIC PROGRAMME

Friday, 26 April 2019

## HT-10 Hot Topic Symposium

**16:00–17:30 Room 5 A**

**Who are the ADHD patients who respond to neurotherapies?**

Chairs: A. Fallgatter, Germany  
K. Rubia, United Kingdom

HT-10-001 Evidence-based EEG-neurofeedback: How, when and for whom  
D. Brandeis, Switzerland

HT-10-002 Results from the double-blind two-site randomised International Collaborative ADHD Neurofeedback (ICAN) study  
M. Arns, The Netherlands

HT-10-003 Optimization of NIRS-based neurofeedback in ADHD by virtual reality  
A. Fallgatter, Germany

HT-10-004 Effectiveness of fMRI-neurofeedback and non-invasive brain stimulation  
K. Rubia, United Kingdom

## HT-11 Hot Topic Symposium

**16:00–17:30 Auditorium IV**

**Hot topic in research: What we need in the field to better understand ADHD? The new big data studies or small studies with well-defined phenotype?**

Chairs: S. Faraone, USA

HT-11-001 We need big data studies rather than small studies with deep phenotyping  
B. Franke, The Netherlands

HT-11-002 We need small studies rather than big data studies with deep phenotyping  
J. A. Sergeant, The Netherlands

## HT-12 Hot Topic Symposium

**16:00–17:30 Auditorium II**

**New concepts and approaches to study ADHD**

Chairs: M. Romanos, Germany  
A. Thapar, United Kingdom

HT-12-001 ESCALife: Evidence-based, stepped care of ADHD along the life-span  
M. Romanos, Germany

HT-12-002 Population neuroscience of the adolescent brain: Outlining possible strategies for stratified preventive strategies in ADHD  
T. Paus, Canada

HT-12-003 The NIH ECHO initiative for examination of environmental factors contributing to neuropsychiatric disorders including ADHD  
J. Schweitzer, USA

HT-12-004 Is there yet a role for longitudinal epidemiological studies and natural experiments to inform our understanding of ADHD?  
A. Thapar, United Kingdom

## HT-13 Hot Topic Symposium

**16:00–17:30 Room 5 C**

**Pre-, peri- and postnatal risk factors in the development of ADHD**

Chairs: M. E. Narad, USA  
I. C. K. Wong, United Kingdom

HT-13-001 Prenatal antidepressant use and risk of ADHD in offspring: Population based cohort study  
I. C. K. Wong, United Kingdom

HT-13-002 Pregnancy-induced hypertension and other early life influences in the development of ADHD: Results from the IDEFICS study  
I. Pigeot, Germany

HT-13-003 Is intrauterine exposure to acetaminophen associated with emotional and hyperactivity problems during childhood?  
L. Tovo-Rodrigues, Brazil

HT-13-004 Secondary ADHD in children and adolescent 5 to 10 years after traumatic brain injury  
M. E. Narad, USA

## HT-14 Hot Topic Symposium

**16:00–17:30 Auditorium I**

**The controversial use, new use, and misuse of psychostimulants**

Chairs: B. Sahakian, United Kingdom  
M. Stein, USA

HT-14-001 Ethical issues in the use of psychostimulants  
M. Stein, USA

HT-14-002 Cognitive enhancers in ADHD and healthy people  
B. Sahakian, United Kingdom

# SCIENTIFIC PROGRAMME

Friday, 26 April 2019

- HT-14-003 Methylphenidate in the initial treatment of acute mania  
U. Hegerl, Germany
- HT-14-004 The use of psychostimulant medication to treat ADHD in elite athletes: A performance and health perspective  
R. Factor, USA

## HT-15 Hot Topic Symposium

- 16:00–17:30 Auditorium III**  
**ADHD, autism and Tourette syndrome: Studies on overlap and divergence**  
Chairs: N. Forde, Canada  
M. Hoogman, The Netherlands
- HT-15-001 Findings from the ENIGMA ASD working group  
D. van Rooij, The Netherlands
- HT-15-002 Findings from the ENIGMA ADHD working group  
M. Hoogman, The Netherlands
- HT-15-003 ADHD and Tourette syndrome  
N. Forde, Canada
- HT-15-004 Eye-tracking in ADHD and Autism Spectrum Disorders  
C. Freitag, Germany

## RC-04 Research Consortia Symposium

- 16:00–17:30 Room 5 B**  
**Eunethydis consortium**  
Chairs: T. Banaschewski, Germany  
D. Coghill, Australia
- RC-04-001 Comparative efficacy and tolerability of ADHD medications  
S. Cortese, United Kingdom
- RC-04-002 Long-term safety in ADHD treatment: Results from the ADDUCE project  
A. Zuddas, Italy
- RC-04-003 Growing out or with ADHD: How to improve continuity of support when transitioning from adolescence into adulthood  
N. Adamo, United Kingdom

## ES-01 Educational Seminars

- 17:45–18:45 Room 1.02**  
**Women ADHD – specificity of symptoms**  
Chairs: A. Rodrigues, Portugal  
M. R. Neves, Portugal  
*see page 41*

## ES-02 Educational Seminars

- 17:45–18:45 Auditorium III**  
**Psychoeducation, cognitive-behavioural treatment and new non-pharmacological interventions for adult ADHD patients**  
Chair: A. Philipsen, Germany  
*see page 41*

## ES-03 Educational Seminars

- 17:45–18:45 Auditorium IV**  
**Assessment strategies of ADHD in adults**  
Chair: W. Retz, Germany  
*see page 41*

## ME-01 Meet-the-Expert-Session

- 17:45–18:45 Room 1.03**  
**Why are adolescents with ADHD so hard to treat?**  
Chair: M. Stein, USA  
*see page 43*

## ME-02 Meet-the-Expert-Session

- 17:45–18:45 Room 1.04**  
**How do I treat patients at the Adult ADHD Program in the Massachusetts General Hospital?**  
Chair: J. Biederman, USA  
*see page 43*

## ME-03 Meet-the-Expert-Session

- 17:45–18:45 Room 1.08**  
**ADHD and giftedness**  
Chair: I. Manor, Israel  
*see page 43*

# SCIENTIFIC PROGRAMME

Saturday, 27 April 2019

## PL-02 Plenary Session

**08:30–10:30 Auditorium I**

### Update on ADHD neurobiology and pathogenesis

Chairs: S. Faraone, USA  
M. Gerlach, Germany

**PL-02-001** Where we are right now 10 years later after the first paper on ADHD brain maturation delay?  
M. Hoogman, The Netherlands

**PL-02-002** Defining the neural substrate of adult outcome of childhood ADHD  
J. K. Buitelaar, The Netherlands

**PL-02-003** Update on genetic and environmental influences on ADHD  
S. Faraone, USA

**PL-02-004** Is mind wandering an essential marker of ADHD?  
P. Asherson, United Kingdom

**10:30 – 11:00 Coffee Break**

## LN-02 Late Breaking News

**10:30–11:00 Pavilion 4**

Chairs: A. Caye, Brazil  
K. Ellison, USA

**LN-02-001** ADHD and lifetime cannabis use: Genetic overlap and causality  
J. A. Ramos Quiroga, Spain

*(Supported by an unrestricted grant from MEDICE)*

## PC-01 Pro-Con-Debate

**11:00–12:30 Auditorium I**

### Do we need to treat subthreshold ADHD?

Moderator: J. Thome, Germany  
Proponent: J. Biederman, USA  
Opponent: D. Coghill, Australia

## P-15 Guided Poster Tour

**12:45–14:15 Pavilion 5**

### Experimental models

Chair: P. Riederer, Germany

**P-15-001** Thyroid hormone-responsive gene overexpression in the striatum leads to the development of inattentive-like phenotype in mice  
C.-J. Botanas, Republic of Korea

R. J. Custodio, M.-K. Kim, H.-J. Lee, A. Abiero, L. V. Sayson, H.-J. Kim, Z.-Y. Ryoo, J.-H. Cheong

**P-15-002** Effects of acupuncture at “Sanyinjiao” (SP6) and “Baihui” (GV20) on the behavior and monoamine neurotransmitter in prefrontal cortex of ADHD model rats  
X. Ni, People’s Republic of China

M. Zheng

**P-15-003** Excitatory/inhibitory imbalance in the Gad1b ADHD zebrafish model  
M. Romanos, Germany

A. D’Orazio, T. Luffe, C. Nilp, C. Lillesaar, C. Drepper

**P-15-004** An eye on ADHD: Can the retina be used as a diagnostic support tool?  
A. P. Silva, Portugal

M. H. Madeira, V. Coelho-Santos, R. A. Leitão, R. Boia, C. Fontes-Ribeiro, R. Fernandes

**P-15-005** Knocking down cntnap2 displayed hyperactivity symptom of ADHD in zebrafish  
C. Wei, Macao

W. Yufeng, Y. Li

**P-15-006** Effect of Catalpol on behavior and neurodevelopment in juvenile spontaneously hypertensive rat model of ADHD  
X. Ni, People’s Republic of China

H. Yuan

## P-16 Guided Poster Tour

**12:45–14:15 Pavilion 5**

### Non-pharmacological treatment – adults

Chair: A. Philipsen, Germany

**P-16-001** Cognitive-behavioral group therapy for ADHD inattentive type: A pilot study of a new treatment protocol  
E. Eskilsson Strålin, Sweden

L. Thorell, S. Bölte, T. Lundgren, B. Bohman



- P-16-002** Two-year follow-up from baseline of the AIMAC randomised controlled trial: Does treatment of mothers in multigenerational ADHD also help children with ADHD in the long term?  
J. Geissler, Germany  
T. Vloet, C. Jaite, E. Graf, A. Warnke, C. Jacob, B. Haack-Dees, K. Schneider-Momm, S. Matthies, M. Rösler, M. Retz, A. von Gontard, E. Sobanski, L. Poustka, M. Colla, C. Freitag, A. Häge, M. Holtmann, K. Becker, A. Philipsen, T. Jans
- P-16-003** Effects of a dialectical behavioral therapy-based group treatment for adults with ADHD: A controlled multi-center study  
A. Halmøy, Norway  
A. Ring, B. Ubstad, M. Møller, T. Lien, E. K. Munkhaugen, M. Fredriksen
- P-16-004** PEGASUS psychoeducational groups for adults with ADHD and their significant others/family members  
T. Hirvikoski, Sweden  
T. Lindström, J. Carlsson, E. Waaler, J. Jokinen, S. Bölte
- P-16-005** Mindfulness-based behavioral group therapy for adult ADHD: A pilot study  
I. Kuchler, Germany  
H. C. Siemoneit, N. Schulze, P. Tonn
- P-16-006** The effects of peer co-led educational group intervention for adults with ADHD: Preliminary results of a randomized controlled pilot study  
M. L. Lara-Cabrera, Norway  
I. Mundal, C. Schröder, I. Kolltveit, A. Mandahl, A. M. Hassel, T. Torgersen, J. Vaag
- P-16-007** A comparison of efficacy between group Cognitive Behavioral Therapy versus Cognitive Behavioral Therapy combined with medication in adult ADHD  
M. Pan, People's Republic of China  
F. Huang, M. Zhao, Y. Wang, Y. Wang, Q. Qian
- P-16-008** Using memory techniques to learn: How students with attention deficit disorder can benefit from the use of mnemonics  
R. van de Lint, The Netherlands  
M. Bosman
- P-16-009** Predictors of neurofeedback training outcome in ADHD and healthy participants  
L. Weber, Germany  
T. Ethofer, A.-C. Ehli
- P-16-010** Non-invasive brain stimulation in ADHD: A systematic review and meta-analysis  
S. Westwood, United Kingdom  
J. Radua, K. Rubia

**P-17****Guided Poster Tour****12:45–14:15****Pavilion 5****Non-pharmacological treatment – children and adolescents I**

Chair: D. Brandeis, Switzerland

- P-17-001** The use of neurofeedback for diagnosis of ADHD/ADD  
H. Abdeldayem, Egypt
- P-17-002** Non pharmacological treatment of ADHD: New technological techniques (NFB, CES, CCT)  
H. Abdeldayem, Egypt  
S. Abdeldayem
- P-17-003** Organizational skills training or neurofeedback, combined with pharmacotherapy in the treatment of school-aged children with ADHD  
H. Azouz, Egypt  
F. Abdel-Latif, T. Omar, M. Khalil, M. Abdel Maksoud
- P-17-004** Treatment of media and internet use disorders in ADHD patients: Four years of experience with the SOMOSA-MediaLab concept  
O. Bilke-Hentsch, Switzerland
- P-17-005** fNIRS-based neurofeedback training normalizes brain functioning in children with ADHD  
F. Blume, Germany  
A.-C. Ehli, G. Preussner, V. Mayer, J. Hudak, T. Dresler, J. Kühnhausen, T. J. Renner, C. Gawrilow
- P-17-006** Mediterranean diet and ADHD: A cross sectional study  
J. A. Blumenfeld Olivares, Spain  
I. San Mauro Martin
- P-17-007** When parents refuse psychopharmacotherapy for ADHD in their children: Mindfulness-based intervention as an add-on to behavior therapy in an eight-year-old boy with ADHD  
V. Boricevic Marsanic, Croatia
- P-17-008** Dietary intervention as additive option in ADHD therapy  
C. Clement, Germany  
A. Doelp, L. Overdick, N. Blazynski, K. Schneider-Momm, H.-W. Clement, E. Schulz, C. Fleischhaker, J. Buehlmeier, L. Libuda, P. Heiser

# SCIENTIFIC PROGRAMME

Saturday, 27 April 2019

- P-17-009 Goal management training in the enhancement of measures of inhibitory control and cognitive flexibility  
L. Nunes, Brazil  
A. Seabra
- P-17-010 Understanding the neuropsychological mechanism of a self-monitoring intervention in the classroom for symptoms of ADHD: A pilot study  
M. Sluiter, The Netherlands  
Y. Groen, P. de Jonge, O. Tucha

|             |                           |
|-------------|---------------------------|
| <b>P-18</b> | <b>Guided Poster Tour</b> |
|-------------|---------------------------|

**12:45–14:15** **Pavilion 5**

**Non-pharmacological treatment – children and adolescents II**

- Chair: S. Cortese, United Kingdom
- P-18-001 Intervention for executive functions and self-regulation in the classroom context reduces indicators of inattention and hyperactivity in elementary school children  
L. R. Carreiro, Brazil  
C. Carla Nunes Cantiere, N. Sant'Anna da Silva, A. P. Roim Micieli, A. P. Soares de Campos, L. Barcellos da Rocha, A. Gotuzo Seabra
- P-18-002 fMRI neurofeedback of right inferior frontal cortex leads to increased functional connectivity in a fronto-cingulo-striatal cognitive control network in adolescents with ADHD  
M. Criaud, United Kingdom  
M. Wulff, A. Alegria, H. Brinson, G. Barker, D. Stahl, V. Giampietro, K. Rubia
- P-18-003 Increased left inferior fronto-striatal activation during error monitoring after fMRI neurofeedback of right inferior frontal cortex in ADHD  
M. Criaud, United Kingdom  
M. Wulff, A. Alegria, G. Barker, V. Giampietro, K. Rubia
- P-18-004 Determining the effectiveness of parent-child interaction therapy on reduction of impulsivity among boy contracted ADHD  
M. Darini, Iran
- P-18-005 Determining the effectiveness of Emotion-focused Therapy (EFT) on reduction of anxiety among girls contracted ADHD  
M. Darini, Iran  
D. Darini, D. Darini

- P-18-006 Be mindful of alternatives to ADHD treatments  
I. de Oliveira, Portugal  
R. Ferreira Carvalho
- P-18-007 FocusLocus: Management gaming system for educational achievement and social inclusion for ADHD  
M. Sanabra, Spain  
A. Del Val
- P-18-008 VR.school: A virtual reality training for children and adolescents with ADHD  
A. Felnhöfer, Austria  
J. X. Kafka, K. Krösl, O. D. Kothgassner
- P-18-009 A qualitative analysis of parent' adaptive tasks and coping skills during the shared decision-making stimulant titration in ADHD care  
E. Fletcher, Canada  
A. Samson, P. Robaey

|             |                           |
|-------------|---------------------------|
| <b>P-19</b> | <b>Guided Poster Tour</b> |
|-------------|---------------------------|

**12:45–14:15** **Pavilion 5**

**Non-pharmacological treatment – children and adolescents III**

- Chair: D. Coghill, Australia
- P-19-001 Evaluation of the outcomes and experiences of participants in a community group-based intervention for parents of young people diagnosed with ADHD  
R. Gonzalez, United Kingdom  
M. Afelumo, S. Stephens, H. Haizel, R. Sala
- P-19-002 Psychopharmacological and non-pharmacological intervention increases the working memory in children with ADHD: A single case study  
R. I. Ismail, Indonesia  
T. Wiguna
- P-19-003 Neurofunctional and behavioural predictors of fMRI-neurofeedback learning in ADHD  
S.-L. Lam, United Kingdom  
M. Criaud, A. Alegria, M. Wulff, G. Barker, V. Giampietro, K. Rubia
- P-19-004 A brain-computer interface-based programme for comorbid ADHD and Autism Spectrum Disorder  
C. G. Lim, Singapore  
X. W. Wendy Poh, S.-H. Jane Teo, C. Guan, T.-S. Lee

- P-19-005** Day-to-day effects of a self-regulation intervention on the ADHD symptoms of school children  
U. Schwarz, Germany  
M. Reuter, J. Kühnhausen, C. Gawrilow
- P-19-006** Metacognitive executive function training for preschool children with ADHD: A randomized controlled study  
L. Shuai, People's Republic of China  
J. Zhang, W. Li, S. Wang
- P-19-007** Mindfulness for children with ADHD and Mindful Parenting (MindChamp): A qualitative study on facilitators, barriers and effects  
N. Siebelink, The Netherlands  
F. van Horssen, S. van Rosmalen-Kaijdoe, J. Holtland, J. Buitelaar, S. Bögels, A. Speckens, C. Greven
- P-19-008** Auditory noise treats cognitive symptoms in ADHD more efficiently than stimulant medication. Is the Smartnoise application a new possible treatment of inattention in school children?  
G. B. W. Söderlund, Norway  
P. Gustafsson
- P-19-009** Effectiveness of cognitive training for school-aged children and adolescents with ADHD: A systematic review  
A. Veloso, Portugal  
S. Vicente, M. Filipe

|             |                           |
|-------------|---------------------------|
| <b>P-20</b> | <b>Guided Poster Tour</b> |
|-------------|---------------------------|

**12:45–14:15** **Pavilion 5**

**Pharmacological treatment I**

- Chair: J. Thome, Germany
- P-20-001** Examination of different responder criteria applied post hoc to select short-term, randomized, controlled trials of lisdexamfetamine dimesylate in children and adolescents with ADHD  
T. Banaschewski, Germany  
J. H. Newcorn, D. R. Coghill, J. Chen, T. Werner-Kiechle
- P-20-002** Long-acting form of Guanfacine: Better as a combination therapy with stimulants?  
A. Band, United Kingdom  
H. Shing
- P-20-003** Evaluation of the response of lisdexamfetamine in children and adolescents with ADHD: Quasi-experimental study  
E. Barragán Pérez, Mexico  
J. C. García Beristain

- P-20-004** ADHD polygenic risk and drug treatment response in over 15,000 ADHD cases  
I. Brikell, Denmark  
T. Wimberley, E. Agerbo, P. B. Mortensen, S. Dalsgaard
- P-20-005** REIMAGINE: A basket study on aggression in CNS disorders, including adult ADHD, using vafidemstat – the first epigenetic compound in CNS clinical research  
R. Bullock, Spain  
S. Gutierrez, T. Ramos, M. Valverde, C. Buesa, T. Maes
- P-20-006** Relationship between baseline ADHD severity and the efficacy of pharmacological treatment for ADHD: A meta-analysis and meta-regression  
X. Castells Cervello, Spain  
M. Ramon, R. Cunill, D. Serrano
- P-20-007** Use of ADHD medication in pregnancy in Norway, 2005–2015  
J. Cohen, Norway  
Ø. Karlstad, K. Furu
- P-20-008** ADHD or bipolar disorder – methylphenidate induced mania?  
R. Ferreira Carvalho, Portugal  
I. de Oliveira, H. Simião
- P-20-009** Use of ADHD medications in Sweden: A nationwide study  
P. Salmi, Sweden  
Y. Ginsberg
- P-20-010** Evaluating the use and knowledge of complementary and alternative medicines in paediatric ADHD  
P. Robaey, Canada  
H. Mazhar, C. Harris

|             |                           |
|-------------|---------------------------|
| <b>P-21</b> | <b>Guided Poster Tour</b> |
|-------------|---------------------------|

**12:45–14:15** **Pavilion 5**

**Pharmacological treatment II**

- Chair: J. K. Buitelaar, The Netherlands
- P-21-001** Combination therapy with stimulants and non-stimulants in ADHD: Effectiveness and tolerability  
S. Gnanavel, United Kingdom
- P-21-002** Indications for antipsychotic use in children and adolescents with neurodevelopmental disorders: A retrospective study  
S. Gnanavel, United Kingdom

# SCIENTIFIC PROGRAMME

Saturday, 27 April 2019

- P-21-003**      **Pharmacological interventions for ADHD in preschool children: A systematic review**  
W. Gurgel, Brazil  
R. Aoyama, G. Polanczyk
- P-21-004**      **ADAPT – ADHD medication and predictors of treatment outcome**  
L. Halldner Henriksson, Sweden  
L. Lundberg, K. Malmberg, C. Hellner, P. Lichtenstein, J.-O. Larsson, E. Serlachius
- P-21-005**      **Analysis of projects funded by NSFC to study ADHD with traditional Chinese medicine**  
X. Han, People's Republic of China  
T. Chen
- P-21-006**      **Clinical characteristics and pharmacotherapy of adults with ADHD in Japan**  
Y. Hanawa, Japan  
W. Hayashi, Y. Iwami, K. Aoyagi, D. Nakamura, A. Iwanami
- P-21-007**      **A novel, modified release drug delivery technology containing Amphetamine-Ion exchange complexes**  
B. Herman, USA  
T. R. King, A. Pardo, J. C. Kando
- P-21-008**      **Pulse rate and blood pressure outcomes from a long-term study of guanfacine extended release in children and adolescents with ADHD**  
M. Huss, Germany  
A. Ramos-Quiroga, B. Dirks, J. Gu, B. Robertson, J. H. Newcorn
- P-21-009**      **Randomized, double-blind, placebo-controlled, phase 3 study of guanfacine extended release in adults with ADHD**  
A. Iwanami, Japan  
K. Saito, M. Fujiwara, D. Okutsu, H. Ichikawa
- P-21-010**      **A retrospective study to understand emerging themes from using long acting guanfacine in 70 children and young people with ADHD in a secondary care setting in UK**  
R. Jainer, United Kingdom  
R. Wilkin, C. Yemula
- P-21-011**      **Development of a drug treatment pathway for formulary approval for young people with ADHD in a secondary care setting in UK jointly by Pharmacist and Paediatrician (Specialist) in 2017**  
R. Jainer, United Kingdom  
J. Yates

## P-22

## Guided Poster Tour

**12:45–14:15**

**Pavilion 5**

### Pharmacological treatment III

Chair: A. Zuddas, Italy

- P-22-001**      **Stimulant treatment in patients with ADHD and comorbid Autism Spectrum Disorder**  
V. Johansson, Sweden  
Z. Chang, M. Taylor, C. Hellner, H. Larsson, L. Halldner
- P-22-002**      **Open-label dose-optimization of an amphetamine extended release oral suspension in children with ADHD**  
J. Kando, USA  
A. Cutler, T. King, A. Pardo, B. Herman
- P-22-003**      **Duration of pharmacological treatment of ADHD: A Norwegian population-based study**  
Ø. Karlstad, Norway  
K. Furu
- P-22-004**      **Combination treatment with guanfacine extended release and blonanserin for Tourette's disorder comorbid with ADHD: A case report**  
K. Kawabe, Japan  
F. Horiuchi, S.-I. Ueno
- P-22-005**      **Treatment adherence and domains of dysfunction in female and male patients with adult ADHD: A retrospective chart review**  
O. Kilic, Turkey  
A. Erkan Yuce, B. Semerci
- P-22-006**      **Stimulant therapy in a case of ADHD and multiple sclerosis**  
M. Koelle, Germany  
M. Senel, K. Heckel, G. Groen
- P-22-007**      **Herb-drug interaction causality assessment in paediatric adverse event reports associated with ADHD medication**  
H. Mazhar, Canada  
P. Robaey, C. Harris, B. Foster, C. Necyk
- P-22-008**      **Treat ADHD first: PHQ-9 score reduction and relief from depressive symptoms with psychostimulant monotherapy**  
J. McClelland, USA  
K. Hashimoto
- P-22-009**      **Children with ADHD using methylphenidate: Analysis of executive functions, attention and verbal fluency**  
C. Minervino, Brazil  
L. Cruz

|             |                           |
|-------------|---------------------------|
| <b>P-23</b> | <b>Guided Poster Tour</b> |
|-------------|---------------------------|

**12:45–14:15****Pavilion 5****Pharmacological treatment IV**

Chair: M. Stein, USA

**P-23-001** Treating for two: Pregnant women with ADHD

M. Moreno, Portugal

D. Pereira, F. Vian, T. Prior Filipe, R. Costa

**P-23-002** Sociodemographic and treatment features of girls with ADHD referring to a "ADHD Outpatient Clinic" in a University Hospital in Turkey

D. Oztop, Turkey

M. Uytun, E. Akçay

**P-23-003** Quantitative strategies to compare a priori efficacy of methylphenidate regimens based on pharmacokinetic models

P. Robaey, Canada

S. Soufsaf, G. Bonnefois, F. Nekka, J. Li

**P-23-004** Lisdexamfetamine in ADHD and comorbid bulimia nervosa

M. Ruiz, Spain

A. Cano, C. Campos, R. Martín, M. T. Iglesias

**P-23-005** Comparative efficacy of methylphenidate and atomoxetine on social problems in youths with ADHD

H.-H. Shih, Taiwan

C.-Y. Shang, S. S.-Fen Gau

**P-23-006** Clinical, neuropsychological and pharmacogenetic predictors of methylphenidate response in a sample of children and adolescents with ADHD

M. Vallejo Valdivielso, Spain

A. Díez Suárez, P. de Castro Manglano, J. J. Marín Méndez, V. Pereira Sánchez, C. Soutullo Esperon

**P-23-007** Monitoring ADHD in children treatment with a new biological marker of ADHD

P. Varela, Spain

J. A. Ramos-Quiroga, H. Super, J. Cañete

**P-23-008** Chart review of Canadian children/adolescents with ADHD receiving guanfacine extended-release: Patient subgroup analyses

T. Werner-Kiechle, Switzerland

S. K. Gill, K. Handelman, C. J. Reaume, J. van Stralen

**P-23-009** Machine learning based ADHD medication response prediction

Y. Zhong, People's Republic of China

Y. Su, Q. Cao, L. Sun, Y. Wang, Z. Yang, L. Yang

**P-23-010** A clinical observation on curative effect of Jing Ling oral liquid on 33 children with ADHD

T. Chen, People's Republic of China

H. Shen, X. Han

|             |                           |
|-------------|---------------------------|
| <b>P-24</b> | <b>Guided Poster Tour</b> |
|-------------|---------------------------|

**12:45–14:15****Pavilion 5****Quality of life/caregiver burden I**

Chair: D. Quinn, Canada

**P-24-001** The Awareness Project: Differences between mothers of children diagnosed with ADHD and mothers of healthy control children as to sleep disorders and symptoms of anxiety, depression and stress

A. Al-Meneea, Saudi Arabia

H. Al-Ammar, A. Al-Eissa, F. Al-Qahtani, S. Al-Qahtani

**P-24-002** ADHD and learning disabilities in school aged children: An example of multimodal intervention

D. Alves, Portugal

B. Pinto, M. Moreira, S. Rowcliffe

**P-24-003** Tell me with whom you walk, and I will tell you who you are: A social network analysis of adolescents with ADHD

M. Arruda, Brazil

R. Arruda, A. C. Andrade Ribeiro

**P-24-004** Proposal for integrating ADHD into primary health care for primary school children in Alexandria, Egypt

H. Azouz, Egypt

A. Saif El-Din, M. Abdel Maksoud

**P-24-005** How's the practice of general psychiatrists for ADHD in adults?

G.-H. Bahn, Republic of Korea

M. Hong, S.-Y. Lee, S.-M. Lee, Y.-S. Lee, B.-S. Kim, Y.-S. Joung, H. K. Yoo, E.-J. Kim, S. I. Lee, D.-H. Han

**P-24-006** Parental intervention program on educational practices and its effects on emotional difficulties of parents of children with ADHD

L. R. Carreiro, Brazil

A. de Fátima Ribeiro, I. Horak Pasqualetto, R. Alves de Souza, N. Sant Anna da Silva, J. P. Pereira Werner da Silva, M. Miyahara Moraes Silva



# SCIENTIFIC PROGRAMME

Saturday, 27 April 2019

- P-24-007** Prevalence of ADHD among elementary school children in religious group and non-religious group  
M. L. De Leon, Republic of Korea
- P-24-008** Barriers and facilitators in understanding ADHD in primary care  
B. French, United Kingdom  
D. Daley, K. Sayal
- P-24-009** Attentional bias to emotional faces in ADHD and sluggish cognitive tempo  
E.-B. Shin, Republic of Korea  
K. Kim, J.-H. Lee
- P-24-010** Links between life satisfaction, aggression, cognitive profile, inflammatory and neuropeptides in adults with ADHD: Preliminary study  
Z. Kupnicka, Poland  
J. Kazmierski

|             |                           |
|-------------|---------------------------|
| <b>P-25</b> | <b>Guided Poster Tour</b> |
|-------------|---------------------------|

**12:45–14:15**

**Pavilion 5**

**Quality of life/caregiver burden II**

Chair: I. Manor, Israel

- P-25-001** The role of executive functions in hyper-focusing and flow experiences in people with ADHD traits  
M. Garcia Pimenta, The Netherlands  
A. Fuermaier, L. Tucha, O. Tucha, Y. Groen
- P-25-002** ADHD in adults: Five components for effective treatment  
J. Grimwade, Australia
- P-25-003** Thinking outside the text: Utilizing video to engage Latino families in global ADHD research and service utilization  
L. Haack, USA  
E. Araujo, J. Meza, K. Alcaraz, A. Mojardín-Heráldez, L. Pfiffner
- P-25-004** Sleep, cognitive function and psychosocial well-being in children with ADHD: A systematic review  
A. Hamilton, United Kingdom  
J. Blackwell, H. Elphick, I. Kellar, A. Weighall, H. Nash
- P-25-005** Unhealthy eating patterns of adults with ADHD  
S. Hershko, Israel  
Y. Pollak
- P-25-006** Questionnaire development needs of adults with ADHD: Results of the Pre - Unmet Needs Inventory - adult ADHD  
S. Herweg, Germany  
P. Tonn

- P-25-007** Development of social skills rating scale for ADHD adolescents: Preliminary study  
M.-S. Lee, Republic of Korea  
J.-H. Lee, H.-J. Lee, D.-S. Kim
- P-25-008** Systemic deficit of attention of child protection children: Implications for assessment, intervention and diagnosis  
M. Lynch, Australia
- P-25-009** Women & ADHD functional impairments: Beyond the obvious  
N. Lynn, USA  
C. Mulder
- P-25-010** Social dysfunctioning as a possible marker for ADHD  
A. F. Sá Carneiro, Portugal  
O. Queirós, C. Calhau, M. Figueiredo-Braga
- P-25-011** ADHD symptom fluctuations and experiences of nature in children's daily life  
M. Reuter, Germany  
U. Schwarz, J. Kühnhausen, C. Gawrilow

|             |                           |
|-------------|---------------------------|
| <b>P-26</b> | <b>Guided Poster Tour</b> |
|-------------|---------------------------|

**12:45–14:15**

**Pavilion 5**

**Quality of life/caregiver burden III**

Chair: S. Kooij, The Netherlands

- P-26-001** Living with ADHD: A meta-analysis review of quantitative research on children's and adolescent's experiences and understanding of their ADHD  
N. Ringer, Sweden
- P-26-002** A process evaluation of the ADHD changing lives initiative  
O. Moran, Ireland  
L. Carragher
- P-26-003** ADHD under forensic context: A supreme sanctuary  
M. Moreno, Portugal  
D. Pereira, F. Vian, T. Prior Filipe, R. Costa
- P-26-004** Interventions to improve social competence in adolescents with ADHD: A systematic review and meta-analysis  
S. Morris, Australia  
J. Sheen, M. Ling, D. Foley, E. Sciberras
- P-26-005** Short-term effects of a peer co-led educational programme to parents with ADHD children: A study protocol  
I. Mundal, Norway  
R. W. Gråwe, H. Johansen, B. Gjervan, J. Vaag, M. L. Lara-Cabrera

- P-26-006** Sleep patterns in an ADHD sample: A latent class analysis  
J. D. Palacio, Colombia  
S. Gomez, D. Aguirre Acevedo
- P-26-007** Prognostic factors related with "unmet need" in adolescents with ADHD  
L. Palacios Cruz, Mexico  
A. Arias-Caballero De Miguel, E. M. Cárdenas Godínez, R. Aguerre Estevez, M. Feria Aranda, L. Sosa Mora, A. Frago, M. Rosetti, K. Garza Gallegos, F. Galicia- Moreno, M. d. Carmen Lara Muñoz, P. Mayer-Villa, D. A. Fernández Garza, R. E. Ulloa Flores
- P-26-008** ADHD: Straight talk about suicide  
D. Pereira, Portugal  
M. Moreno, F. Vien, A. Ponte, M. Mendes, T. Teodoro, F. Gonçalves
- P-26-009** Screen time exposure and sleep among children with ADHD  
J. Matias, Portugal  
M. Matias, R. Garrido, C. Granja, A. Duarte, L. Lourenço, L. Rocha, L. Ventosa, M. J. Fonseca
- P-26-010** Determining if ADHD has a causal role on educational attainment using Mendelian randomization  
E. Stergiakouli, United Kingdom  
C. Dardani, B. Leppert, L. Riglin, A. Thapar, L. Howe, G. Davey Smith, K. Tilling, E. Anderson

|             |                           |
|-------------|---------------------------|
| <b>P-27</b> | <b>Guided Poster Tour</b> |
|-------------|---------------------------|

**12:45–14:15** **Pavilion 5**

**Quality of life/caregiver burden IV**

Chair: A. Reif, Germany

- P-27-001** Managing children with challenging behaviour. Parents' meaning-making processes in relation to their children's ADHD diagnoses  
N. Ringer, Sweden  
M. Scheja, A. Gustavsson, J. Wilder
- P-27-002** ADHD in urban China: Implementing ADHD pathways in a paediatric and in a mental health care system  
P. Robaey, Canada  
L. Fei, Y. Li
- P-27-003** The assessment of marital adjustment amongst parents of children diagnosed with ADHD  
A. Rodopman Arman, Turkey  
B. Cangut, C. Aksu, E. Dursun, E. Ignezi, M. Akman, S. Hidirolu, M. Karavus

- P-27-004** Reading components in ADHD and dyslexia: Differential cognitive profiles in Brazilian adolescents  
A. Seabra, Brazil  
C. Branco, G. Brito
- P-27-005** You and me and ADHD: A course for couples  
A. M. Teigen, Norway  
L. Lotherington
- P-27-006** Sickness absence recommendation among outpatients with ADHD and comorbidity: A latent class analysis  
A. Trantou, Sweden
- P-27-007** Maternal ADHD symptoms and infants' temperament predict maternal stress and childhood maltreatment during the first year of life  
J. Verano de Oliveira, Brazil  
E. Constantino Miguel, A. M. Chiesa, D. Fatori, G. Vanoni Polanczyk
- P-27-008** Young people with ADHD: A qualitative investigation of factors for a successful personal recovery  
S. J. Edwards, Australia  
W. Chen, M. Toner
- P-27-009** Retrospective medical chart review evaluating burden of illness in adults with ADHD: Follow-up data after 2 years  
E. Ahnemark, Sweden  
M. Di Schiena, A.-C. Fredman, E. Medin, J. Söderling, Y. Ginsberg
- P-27-010** Prevalence and characteristics of bullying and cyberbullying in adolescents with ADHD: A cross-sectional study in Granada (Spain)  
D. Fernandez Reyes, Spain  
O. Herreros, A. P. Vázquez-González, F. Díaz-Atienza

|             |                           |
|-------------|---------------------------|
| <b>P-28</b> | <b>Guided Poster Tour</b> |
|-------------|---------------------------|

**12:45–14:15** **Pavilion 5**

**Miscellaneous**

Chair: S. Kittel-Schneider, Germany

- P-28-001** Impact of antiepileptic treatment in attentional control measured by continuous performance test  
E. M. Alarcón de la Luz, Mexico  
E. Barragán Pérez, J. C. García Beristain
- P-28-002** Implications of brief ADHD training sessions for increasing educators' knowledge and understanding of ADHD  
S. Brock, Ireland  
L. Carragher, C. O'Connor

# SCIENTIFIC PROGRAMME

Saturday, 27 April 2019

- P-28-003** Exploring social worker's knowledge deficits regarding adults with pre-comorbid attention disorders  
D. Brown, USA
- P-28-004** What is known about ADHD? A study in a Portuguese population  
J. Cardoso, Portugal  
I. Maio, I. Vaz Matos, D. Gonzaga, C. Prior
- P-28-005** Searching for new ways to define and evaluate attention  
E. Fehr, Austria  
H.-J. Schweizer, J. Kane, W. Peter
- P-28-006** ADHD and psychosis association: A case-report and literature review  
M. Ferraz de Liz, Portugal  
M. Falcão, A. F. Lopes
- P-28-007** ADHD and success in military service in males in the Northern Finland Birth Cohort 1986  
A.-H. Halt, Finland  
J. Koskela, J. Uusitalo, P. Niemi, J. Veijola, T. Hurtig
- P-28-008** ADHD and substance use disorders: Two sides of the same coin  
M. Moreno, Portugal  
D. Pereira, F. Vian, T. Prior Filipe, R. Costa
- P-28-009** Negative association between inattention symptoms and mentalizing in community adolescents  
E. Poznyak, Switzerland  
L. Morosan, N. Perroud, M. Speranza, D. Badoud, M. Debbané
- P-28-010** Using a foraging activity to evaluate the impact of cognitive dysfunction in ADHD  
M. Rosetti, Mexico  
J. Ojeda, L. Palacios, F. De la Peña, R. Hudson, E. Ulloa
- P-28-011** The late dementia with different type delusions  
A. Sidenkova, Russia
- P-28-012** A clinic-based survey of teenagers with and without ADHD to understand their sleep habits, impact of poor sleep and whether gender differences exist  
C. Yemula, United Kingdom  
E. Musgrave, S. Ajmal, A. Khan, T. Banerjee, R. Sesham, R. Jainer
- P-28-013** A lady-like discrete portrait: ADHD in women  
M. Moreno, Portugal  
D. Pereira, F. Vian, T. Prior Filipe, R. Costa

14:00 – 14:30

Coffee Break

## HT-16

## Hot Topic Symposium

14:30–16:00

Auditorium III

### Adult ADHD subtypes and comorbid conditions

Chairs: F. Reimherr, USA  
W. Retz, Germany

- HT-16-001** Emotional dysregulation in adults with ADHD: Validity, predictability, severity and comorbidity  
S. Corbisiero, Switzerland
- HT-16-002** The Wender Utah Rating Scale in the evaluation of adults with ADHD, major depression, or generalized anxiety  
F. Reimherr, USA
- HT-16-003** Trait anxiety as a mediator of the association between ADHD symptoms severity and functional impairment  
Y.-H. Oh, Republic of Korea
- HT-16-004** ADHD and anti-sociality  
W. Retz, Germany

## HT-17

## Hot Topic Symposium

14:30–16:00

Auditorium I

### Controversies on AD trajectories

Chairs: L. Arseneault, United Kingdom  
E. Grevet, Brazil

- HT-17-001** Raising red flags for clinicians: When retrospective recall of ADHD symptoms in childhood is even less accurate? Data from the 1993 Pelotas Birth Cohort  
E. Grevet, Brazil
- HT-17-002** Investigating child psychopathology in late-onset ADHD: Controversies in populational studies  
J. Agnew-Blais, United Kingdom
- HT-17-003** The genetics of ADHD across development: Investigation late onset, persistent and remitted ADHD from childhood to young adulthood  
L. Arseneault, United Kingdom
- HT-17-004** Relative immaturity and ADHD diagnosis: A meta-analysis and a natural study in three birth cohorts  
A. Caye, Brazil

# SCIENTIFIC PROGRAMME

Saturday, 27 April 2019

## HT-18 Hot Topic Symposium

**14:30–16:00 Room 5 A**

### ADHD beyond the individual

Chairs: A. Rodrigues, Portugal  
S. Dalsgaard, Denmark

**HT-18-001** Does parent treatment has any impact on ADHD in offspring?  
J. Geissler, Germany

**HT-18-002** Changing teacher's minds about ADHD. How does it make a difference in school intervention?  
A. Rodrigues, Portugal

**HT-18-003** The impact of ADHD on sexuality  
S. Dalsgaard, Denmark

## HT-19 Hot Topic Symposium

**14:30–16:00 Room 5 B**

### Clinical experience and research findings from the Iberic peninsula on ADHD

Chairs: J. Boavida, Portugal  
C. Soutullo Esperon, Spain

**HT-19-001** The implementation of the incredible years program for parents of pre-schoolers with ADHD in a hospital setting: Strengths and limitations  
J. Boavida, Portugal

**HT-19-002** Clinical and neuropsychological characteristics and predictors of methylphenidate response in children and adolescents with ADHD: A naturalistic follow-up study in a Spanish sample  
C. Soutullo Esperon, Spain

**HT-19-003** Transition from adolescence to early adulthood in ADHD  
J. A. Ramos Quiroga, Spain

**HT-19-004** Sleep quality in an adult ADHD clinic  
A. Ponte, Portugal

## HT-20 Hot Topic Symposium

**14:30–16:00 Room 5 C**

### Tribute to the WFADHD medal recipient: Recent findings on ADHD from China

Chair: Y. Wang, People's Republic of China  
Discussant: S. Faraone, USA

**HT-20-001** Recent traditional Chinese medicine findings for ADHD  
Y. Zheng, People's Republic of China

**HT-20-002** Recent genetic findings from Chinese ADHD samples  
L. Yang, People's Republic of China

**HT-20-003** The role of the cell stress-response gene NDRG2 in ADHD susceptibility  
Y. Li, People's Republic of China

## YS-02 Young Scientists' Session II

**14:30–16:00 Auditorium IV**

Chairs: J. K. Buitelaar, The Netherlands  
A. Warnke, Germany

**YS-02-001** Early predictors for late-onset ADHD symptoms  
C. K. Liu, United Kingdom

**YS-02-002** Parent-offspring recurrence of ADHD  
B. S. Solberg, Norway

**YS-02-003** Persistence and neural correlates of Disruptive Mood Dysregulation Disorder in 10-year-old children with ADHD  
M. Mulraney, Australia

**YS-02-004** Neurocognitive markers of late-onset ADHD: A 6-year longitudinal study  
S. Ilbegi, The Netherlands

# SCIENTIFIC PROGRAMME

Saturday, 27 April 2019

## ES-04 Educational Seminars

**16:15–17:15** Auditorium IV

### Recommendations for therapy in school

Chairs: S. Walitza, Switzerland  
R. Drechsler, Switzerland

see page 42

## ES-05 Educational Seminars

**16:15–17:15** Auditorium III

### ADHD and problematic internet use: Treatment options

Chair: S. H. Kollins, USA

see page 42

## ES-06 Educational Seminars

**16:15–17:15** Room 1.02

### Treatment of ADHD and substance abuse

Chair: J. A. Ramos Quiroga, Spain

see page 42

## ME-04 Meet-the-Expert-Session

**16:15–17:15** Room 1.03

### High severity patients with adult ADHD

Chair: F. Reimherr, USA

see page 44

## ME-05 Meet-the-Expert-Session

**16:15–17:15** Room 1.04

### Evidence for treatment of ADHD with psychostimulant medication

Chair: J. Swanson, USA

see page 44

## ME-06 Meet-the-Expert-Session

**16:15–17:15** Room 1.08

### ADHD and food

Chair: S. Cortese, United Kingdom

see page 45





# SCIENTIFIC PROGRAMME

Sunday, 28 April 2019

| PL-03   | Plenary Session   |
|---|---|
| <b>08:30–10:30</b>                                    | <b>Auditorium I</b>   |
| <b>Update on treatment of ADHD over the life-span</b> |   |
| Chairs:   | J. Boavida, Portugal<br>C. Soutullo, Spain  |
| PL-03-001   | Advances in non-pharmacological treatments (food and nutrition-based interventions, non-invasive deep brain stimulation etc.)<br>S. Cortese, United Kingdom |
| PL-03-002   | What comes next? The medication pipeline for treatment of ADHD<br>J. Newcorn, USA   |
| PL-03-003   | Psychosocial and psycho-behavioural treatments (cognitive behavioural therapy, psychoeducation)<br>M. Döpfner, Germany                                      |
| PL-03-004   | How to approach rational treatment of ADHD comorbidity<br>T. Banaschewski, Germany  |

10:30 – 11:00 Coffee Break

| LN-03              | Late Breaking News  |
|--------------------|---|
| <b>10:30–11:00</b> | <b>Pavilion 4</b>   |
| Chairs:            | A. Caye, Brazil<br>K. Ellison, USA  |
| LN-03-001          | Psychosis with methylphenidate or amphetamine in patients with ADHD<br>S. Cortese, United Kingdom |

(Supported by an unrestricted grant from MEDICE)

| PL-04                            | Plenary Session  |
|----------------------------------|--|
| <b>11:00–13:00</b>               | <b>Auditorium I</b>  |
| <b>Future directions in ADHD</b> |  |
| Chairs:                          | P. Riederer, Germany<br>L. A. Rohde, Brazil  |
| PL-04-001                        | ICD-11, DSM-5 revised version, RDoC: What is the future of ADHD diagnosis?<br>L. A. Rohde, Brazil  |
| PL-04-002                        | New strategies in modelling ADHD in humans and animals<br>K.-P. Lesch, Germany   |
| PL-04-003                        | Strategic longitudinal examination of the brain at-risk to bring the concepts of early intervention and prevention to ADHD<br>F. X. Castellanos, USA |
| PL-04-004                        | The promise of digital health for the treatment of ADHD<br>S. H. Kollins, USA  |

## Closing Ceremony

|   |                     |
|---|---------------------|
| <b>13:00–13:30</b>  | <b>Auditorium I</b> |
| <ul style="list-style-type: none"> <li>▶ Congress summary</li> <li>▶ Presentation of the poster prize winners</li> <li>▶ Announcement of the 8<sup>th</sup> ADHD World Congress 2021</li> </ul> |                     |



REGISTER NOW!



18<sup>th</sup> International Congress of ESCAP  
**VIENNA 2019**

DEVELOPMENTAL PSYCHIATRY IN A GLOBALIZED WORLD

30 June – 2 July 2019 | Hofburg Vienna, Austria

[www.escap.eu](http://www.escap.eu)

# PATIENTS' DAY

Sunday, 28 April 2019

**Registration:** Free of charge but mandatory registration.

## PROGRAMME

09:00 – 17:30

Auditorium VI

- 09:00 **Official opening**
- 09:30 – 10:20 **ADHD diagnosis, evaluation and associated problems**  
Chair: T. Cartaxo, Portugal  
**What is ADHD and how do we diagnose it**  
G. Polanczyk, Brazil  
**Which are the most frequent associated problems and what is their relevance**  
C. Filipe, Portugal
- 10:20 – 10:40 **Discussion**
- 10:40 – 11:10 **Coffee Break and networking**
- 11:10 – 12:00 **ADHD therapeutic management**  
Chair: B. Barahona Corrêa, Portugal  
**Non-pharmacologic therapy ADHD and school**  
A. Rodrigues, Portugal  
**Strategies to address defiant behaviours in preschoolers**  
J. Seabra Santos, Portugal  
**ADHD medications**  
C. Soutullo, Spain
- 12:00 – 12:20 **Discussion**

- 12:20 – 13:10 **Adult ADHD**  
Chair: J. Cerejeira, Portugal  
**ADHD in adults**  
E. Grevet, Brazil  
**An adult ADHD sharing his experience**  
A. Ponte, Portugal

13:10 – 13:30 **Discussion**

13:30 – 15:00 **Lunch**

15:00 – 15:15 **The impact of ADHD on the families**  
Association to the support of hyperactive children

15:15 – 17:30 **Ask the experts**  
**Panel of experts:**  
C. Soutullo, Spain  
P. Mattos, Brazil  
D. Coghill, Australia  
J.-A. Ramos-Quiroga, Spain

17:30 **Closing**

# EDUCATIONAL SEMINARS

Friday, 26 April 2019

## ES-01 Educational Seminar

17:45 – 18:45

Room 1.02

### Women ADHD – specificity of symptoms

Chairs: A. Rodrigues & M. Neves, Portugal

The recognition of ADHD in girls and women is a hot topic given the growing evidence of phenotypic differences in males and females. The behavioral expression of similar cognitive and emotional difficulties constitutes a clinical, pedagogical and personal knowledge of the utmost importance in order to reduce the number of cases of female persons who will not be correctly diagnosed. In the case of ADHD, and given the significant impact it has on personal, academic and professional life, it happens that failure to identify this problem leads to misdiagnoses and the implementation of ineffective interventions. This perpetuates the discomfort of girls and women with ADHD who see delayed intervention.

In this Educational Seminar we intend to detail the phenotypic differences according to sex and to detail their evolution throughout the development, referring to the clinical and scientific experience of the lecturers. It is also intended to discuss the significant impact that, throughout the life, ADHD has in the case of female people. An extensive clinical and educational experience exchange is intended for participants in this Seminar based on their own professional experiences.

## ES-02 Educational Seminar

17:45 – 18:45

Auditorium III

### Psychoeducation, cognitive-behavioural treatment and new non-pharmacological interventions for adult ADHD patients

Chair: A. Philipsen, Germany

ADHD over the lifespan can cause severe negative psychosocial consequences. Therefore, beside medication, psychoeducation and behavioral strategies are meaningful additional treatment options. In the course, core elements of (cognitive) behavioral strategies and mindfulness-based strategies are presented. Moreover, complementary treatments such as physical activity and underlying mechanisms are discussed.

## ES-03 Educational Seminar

17:45 – 18:45

Auditorium IV

### Assessment strategies of ADHD in adults

Chair: W. Retz, Germany

The diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults is a complex process especially if the disorder was not diagnosed during childhood. Different databases and data sources have to be considered. The seminar addresses typical psychopathological features of adult ADHD according to DSM-5 and beyond and typical functional problems of adult ADHD patients. Also, the seminar provides an overview of general problems of the assessment, the different steps of the diagnostic process and the instruments which can be useful to diagnose the disorder. Available are interviews, self and observer rating scales. Finally, some unsolved issues in the assessment of ADHD in adults are discussed.

► *Registration fee for Educational Seminars and Meet-the-Expert-Session: EUR 50 per session.  
Only valid in combination with the congress registration fee.*

# EDUCATIONAL SEMINARS

Saturday, 27 April 2019

## ES-04 Educational Seminar

16:15–17:15

Auditorium IV

### Recommendations for therapy in school

Chairs: S. Walitza, Switzerland & R. Drechsler, Switzerland

School-based interventions. Richards et al. (2015) focus on three possible levels of school-based interventions:

- a) on the structure of the class
  - b) on the teacher/educational staff and
  - c) on the student
- a) Interventions on the class structure are e.g. classroom design (low-irritation, few distraction possibilities), type of class leadership by the teacher (alternating phases, varied, group amplifier plans) or use of short phases of physical activity
- b) Interventions at the level of the teacher are primarily education on ADHD, school lesson design tailored to ADHD children (e.g. stronger tutoring programs for weaker students or PC-based instructions), and the use of interactive strategies by the teacher
- c) student-centered interventions are e.g. training methods such as PC-based cognitive training, which can be carried out at school but are not necessarily tied to the school setting, the training of self-management and intention-implementation

The online Help guide (Segal and Smith, 2019) is an example focusing on support the parents to work and communicate with the school, to make individual behavioural plans “The Daily Report Card” to support the child.

A special challenge of the seminar are the different legal aspects and school systems of the different countries. For this issue comments and discussion of the participants are of special interest.

## ES-05 Educational Seminar

16:15–17:15

Auditorium III

### ADHD and problematic internet use: Treatment options

Chair: S. H. Kollins, USA

Patients with ADHD are at increased risk for a wide range of addictive disorders, including cigarette smoking/tobacco use, cocaine use, and cannabis use. In recent years it has also been acknowledged that internet addiction is a real

phenomenon with many features similar to other substance use disorders. The purpose of this educational activity is to survey the literature and describe clinical experience relevant to understanding problematic internet use among patients with ADHD. Developmental considerations will be discussed, along with treatment options.

### Learning Objectives

1. Describe the similarities and differences between problematic internet use/addiction and substance use disorders
2. Understand the clinical features that may place patients with ADHD at increased risk for problematic internet use
3. Evaluate the evidence for different approaches to preventing and treating problematic internet use among patients with ADHD

## ES-06 Educational Seminar

16:15–17:15

Room 1.02

### Treatment of ADHD and substance abuse

Chair: J. A. Ramos Quiroga, Spain

ADHD is considered a risk factor for the development of substance use disorders (SUD). More than 30% of patients with ADHD will develop lifetime SUD. Specifically, ADHD and cannabis use are partly determined by genetic factors; the heritability of ADHD is estimated at 70-80% and of cannabis use initiation at 40-48%. Recent study found that ADHD is causal for lifetime cannabis use, with an odds ratio of 7.9 for cannabis use in individuals with ADHD in comparison to individuals without ADHD. On the other hand, about 20-25% of adult SUD patients fulfill criteria for ADHD. In an international multicenter study, the IASP study, the overall prevalence of adult ADHD in treatment seeking SUD patients was still as high as 14%. It is essential the correct assessment of psychiatric comorbidity in ADHD because the patient's comorbidity profile will influence treatment planning. Simultaneous and integrated treatment of ADHD and SUD, using a combination of pharmac- and psychotherapy, is recommended. Long-acting methylphenidate, extended-release amphetamines, and atomoxetine with up-titration to higher dosages may be considered in patients unresponsive to standard doses. The seminar provides an overview of the treatment of ADHD in patients with SUDs. The multiple challenges that commonly appear during the treatment of this comorbidity are discussed.

# MEET-THE-EXPERT-SESSIONS

Friday, 26 April 2019

## ME-01 Meet-the-Expert-Session

**17:45 – 18:45** **Room 1.03**

### Why are adolescents with ADHD so hard to treat?

Chair: M. Stein, USA

Childhood ADHD typically persists into adolescence, yet medications are often discontinued and motivation for treatment is low. Indeed, suboptimal treatment of ADHD symptoms, emergence of psychiatric comorbidities and exacerbated impairments in response to changing school, social, and family environments can have devastating consequences. Factors in the adolescent, the family and service delivery models that do not fit a life-span disorder such as ADHD contribute to poor outcomes during this critical period. This case-based presentation will highlight therapeutic approaches to young and older adolescents and describe the ADHD Checkup, an innovative treatment strategy based on motivational interviewing and shared decision making within a collaborative care framework to encourage engagement and adherence to multimodal treatment tailored to adolescents. Will also discuss differences from treating childhood ADHD and treatment optimization and augmentation strategies based on clinical characteristics and patient and parent preferences.

## ME-02 Meet-the-Expert-Session

**17:45 – 18:45** **Room 1.04**

### How do I treat patients at the ADHD program in the Massachusetts General Hospital

Chair: J. Biederman, USA

In this session, Professor Biederman will answer questions from the audience on relevant issues on ADHD focused on aspects related to the best clinical practices for diagnosing the disorder and on disentangling effects of main comorbid conditions and on the management of patients across the life cycle with special attention for psychopharmacological interventions for ADHD based on his vast clinical experience in Mass General Hospital at Harvard University and his major role in research protocols in the field.

## ME-03 Meet-the-Expert-Session

**17:45 – 18:45** **Room 1.08**

### ADHD and giftedness

Chair: I. Manor, Israel

'Twice-exceptional' children hold both unique cognitive capacity and some form of disability. Children who are academically gifted or talented (GT) and diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) impose a great challenge for researchers and mental health practitioners. The main reason to focus on children with both GT and ADHD is that their symptomology often manifests in a very complex pattern. Although ADHD is prevalent in highly-intelligent students, in reality two clinical and educational pictures tend to develop: (1) Both mental health professionals and teachers are inclined to focus on ADHD symptoms, which shadow the GT within the same child (A>G); or (2) Once giftedness is identified, both mental health professionals and teachers might ignore the possible existence of ADHD, or under-evaluate its importance (G>A).

This presentation will deal with the reasons for this difficulty to differentiate these children, their specific characteristics, the misleading symptoms that might result in an incorrect diagnosis and will suggest treatment and some practical implications:

1. Being aware and accepting the possibility of this dual diagnosis and its implications
2. Treating both exceptions side by side
3. Treating the inferior social skills, instead of falling to the stigma of "the lonely genius"
4. Allowing more academic and social autonomy

► Registration fee for Educational Seminars and Meet-the-Expert-Session: EUR 50 per session.  
Only valid in combination with the congress registration fee.

# MEET-THE-EXPERT-SESSIONS

Saturday, 27 April 2019

|              |                                |
|--------------|--------------------------------|
| <b>ME-04</b> | <b>Meet-the-Expert-Session</b> |
|--------------|--------------------------------|

**16:15 – 17:15**

**Room 1.03**

**High severity patients with adult ADHD**

Chair: F. Reimherr, USA

The Wender Utah Rating Scale (WURS) detects a pattern of childhood symptoms and behaviors consistent with ADHD persisting into adulthood. There are over 1,000 references to the scale in Google Scholar including at least 30 reports regarding the scale's psychometric properties. In contrast to almost all past reports, we simultaneously assessed the psychometric properties of both the full 60 item WURS and the shorter WURS-25. We also used more diverse and clinically relevant populations: Adults with ADHD (n=137), nonclinical controls (n=120) and psychiatric controls with major depression (n=121) or generalized anxiety disorder (n=109). Both versions generated analogous factors that we labeled disruptive mood & behavior, ADHD, and anxiety/dysphoria. The full WURS generated 2 additional factors: Social and Academic. The ADHD, disruptive mood & behavior, and academic factors were highly correlated ( $r > .8$ ,  $p < .0001$ ) and differed between the ADHD cohort and the non-ADHD groups ( $p < .001$ ). In contrast, neither the anxiety/dysphoria or social factors differed between GAD, MDD and ADHD groups. ADHD subjects with high levels of emotional symptoms which we have labeled ADHD emotional dysregulation presentation had significantly higher scores on the disruptive mood & behavior and anxiety/dysphoria factors other ADHD subjects. The WURS-25 scoring system developed by Wender & Reimherr distinguished the ADHD group from the combined depression and anxiety groups ( $p < .0001$ ) with sensitivity = 62.77% and specificity = 83.93%. The scale successfully separated subjects with ADHD from GAD and MDD. Both WURS versions support a broader conceptualization of ADHD and help to clarify the types of impairment shown by subjects with the disorder.

|              |                                |
|--------------|--------------------------------|
| <b>ME-05</b> | <b>Meet-the-Expert-Session</b> |
|--------------|--------------------------------|

**16:15 – 17:15**

**Room 1.04**

**Evidence for treatment of ADHD with psychostimulant medication**

Chair: J. Swanson, USA

The use of stimulant medications (methylphenidate and amphetamine) to treat symptoms of ADHD has remained controversial despite linear increases in this clinical practice for decades, resulting in high percentages of children identified with ADHD and receiving this treatment (e.g., 11% of 4- to 18-year old children in the USA recognized and 7% treated with stimulant medication). Historically, many previous reviews document effectiveness of short-term treatment of ADHD with stimulant medication (Swanson et al, 1994), and recently additional evidence was summarized by two large and very impressive meta-analyses of randomized clinical trials (Storebo et al, 2015 and Cortese et al, 2018). Both conclude there are large benefits (effect size about 0.8) of short-term treatment, and both highlight lack of controlled studies of long-term treatment. Despite very similar estimates of effect size for short-term treatment, these two meta-analyses differed in recommendations for treatment, based on very different evaluations of "Quality of Evidence". This generated considerable controversy and debate in the literature (Swanson, 2018), which will be summarized and discussed.

In addition, recent studies of long-term self-selected use of medication in clinical practice ("treatment as usual") will be reviewed. The common patterns of use in prospective follow-up studies (e.g., in the MTA; Swanson et al, 2017) and in national registries (e.g., in Sweden; Lichtenstein et al, 2012) will be described. Despite the application of very different methods, these studies indicate that long-term adherence to treatment is poor, and that inconsistent treatment (stopping and starting treatment) is more common than consistent treatment (long durations of continuous or uninterrupted treatment). Recent analyses of reasons for stopping and starting medication will be reviewed. Speculative hypotheses of pharmacological tolerance and neural adaptations (possible mechanisms that could undermine or reduce effectiveness of long-term treatment compared to short-term treatment) will be presented and discussed.

► *Registration fee for Educational Seminars and Meet-the-Expert-Session: EUR 50 per session.  
Only valid in combination with the congress registration fee.*



**ME-06**

**Meet-the-Expert-Session**

**16:15 – 17:15**

**Room 1.08**

**ADHD and food**

Chair: S. Cortese, United Kingdom

In my presentation I will provide an overview of the literature on the association between disordered eating behaviour and ADHD in childhood and in adults, highlighting specific associations with individual eating disorders and possible gender differences. I will also present the overlapping brain circuits in ADHD and obesity. I will finally highlight possible clinical implications for the daily practice.

**REGISTER NOW!**  
 1 July 2019 – deadline for early bird registration



**ESAS**  
European Scientific Association on Schizophrenia and other Psychoses

in cooperation with





## 7th European Conference on Schizophrenia Research (ECSR)

### Schizophrenia and other psychotic disorders: Time for precision medicine?

Organized by the European Scientific Association on Schizophrenia and other Psychoses (ESAS)

## 26 – 28 September 2019 Berlin, Germany

## www.schizophrenianet.eu

CPO HANSER SERVICE is specialist in the field of Conference, Event, Destination and Association Management organizing events of any size throughout Germany and also abroad for more than 35 years.



CONFERENCE – EVENT – DESTINATION – ASSOCIATION MANAGEMENT – IT SOLUTIONS

## We offer you:

- the best congress organization
- state-of-the-art online solutions
- electronic abstract handling
- CME accreditation handling
- effective congress technology
- sponsoring and exhibition acquisition and management
- finance management
- professional tax solutions
- creative event programmes
- websites and apps
- graphic design
- association management

### BERLIN

Paulsborner Straße 44  
14193 Berlin  
fon +49-30-300 669 0  
fax +49-30-305 73 91  
Email: berlin@cpo-hanser.de

### HAMBURG

Zum Ehrenhain 34  
22885 Barsbüttel  
fon +49-40-670 882 0  
fax +49-40-670 32 83  
Email: hamburg@cpo-hanser.de

[www.cpo-hanser.de](http://www.cpo-hanser.de)



## CONGRESS VENUE

Lisbon Congress Center  
Praça das Indústrias 1  
Lisbon 1300-307, Portugal

## CONGRESS REGISTRATION COUNTER

All congress materials and documentation will be available from the congress registration counter located in Foyer C.

### Opening Hours

|                         |             |
|-------------------------|-------------|
| Thursday, 25 April 2019 | 10:00–19:00 |
| Friday, 26 April 2019   | 07:30–18:00 |
| Saturday, 27 April 2019 | 08:00–17:00 |
| Sunday, 28 April 2019   | 08:00–13:00 |

During these opening hours the congress counter can be reached at: + 351 21 89 21 870

The congress counter has the following sections:

- ▶ On-site registration
- ▶ Pre-registration paid
- ▶ Pre-registration unpaid

Your World Federation membership fee can be paid at the on-site registration and at the pre-registration unpaid counter, too.

## REGISTRATION FEES

### Registration and Payment

|   |         |
|---|---------|
| Non-member from Countries A <sup>1</sup>  | EUR 600 |
| Non-member from Countries B <sup>1</sup>  | EUR 500 |
| Member World Federation of ADHD from Countries A <sup>1</sup> , SPDA and CADDRA members | EUR 550 |
| Member World Federation of ADHD from Countries B <sup>1</sup>                           | EUR 450 |
| Students and persons under 35 years*  | EUR 350 |
| Educational Seminars**  | EUR 50  |
| Meet-the-expert Sessions**  | EUR 50  |

<sup>1</sup>) For list of countries A and B, please check the congress website.

\* A copy of the passport and student identity card is necessary.

\*\*Only valid in combination with the congress registration fee.

Registration fee for the participants includes:





- ▶ Admission to all scientific sessions
- ▶ Admission to poster and technical exhibition
- ▶ Final programme
- ▶ Admission to the Opening Ceremony and Networking Reception on Thursday, 25 April 2019

## CERTIFICATE OF ATTENDANCE

Please hand in your evaluation form at the counter for a certificate of attendance.

## NAME BADGES

All participants are requested to wear their name badges at all times during the congress. The colours of the name badges have the following significance:

|   |  |
|---|--|
|    | Delegate   |
|    | Delegate incl. Educational Seminar/Meet-the-Expert-Session |
|   | Exhibitor  |
|  | Staff  |

## CONGRESS LANGUAGE

The congress language is English.

## CONGRESS INFORMATION SYSTEM CO CONGRESS ONLINE®

[www.adhd-congress.org](http://www.adhd-congress.org)

Participants can benefit from the web-based ADHD Congress Information System CO CONGRESS ONLINE®.

The ADHD Congress Information System provides information on:

- ▶ Updated scientific programme
- ▶ Programme by day
- ▶ Programme by formats with accepted abstracts of chairpersons and speakers
- ▶ Programme search
- ▶ List of participants (who is who)
- ▶ List of exhibitors
- ▶ General congress information
- ▶ Private mail box

# GENERAL INFORMATION

## CME CREDITS

The 7<sup>th</sup> World Congress on ADHD, Lisbon, Portugal, 25 – 28 April 2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with



**20 European CME credits** (ECMEC®s).

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at [www.ama-assn.org/education/earn-credit-participation-international-activities](http://www.ama-assn.org/education/earn-credit-participation-international-activities).

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

### EACCME® credits

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form.

### Breakdown of ECMEC®s per day:

|               |                    |
|---------------|--------------------|
| 25 April 2019 | ▶ <b>3 credits</b> |
| 26 April 2019 | ▶ <b>6 credits</b> |
| 27 April 2019 | ▶ <b>7 credits</b> |
| 28 April 2019 | ▶ <b>4 credits</b> |

## WLAN/Wi-Fi

Free Wi-Fi access is available in the Lisbon convention centre. Network: **ADHD2019**, Password: **adhd2019**.

## CONGRESS APP

Get the 7<sup>th</sup> World Congress on ADHD APP for your smart phone now and experience the congress at your fingertips! Quickly find your way through the most up-to-date congress schedule. Stop carrying around piles of paper. Just take the congress with you, wherever and whenever you want!



The APP is completely free and provides iPhone/iPad and Android smartphones users at the 7<sup>th</sup> World Congress on ADHD 2019 in Lisbon.



The ADHD 2019 APP is powered by GLOBIT GmbH in cooperation with esanum GmbH.

Further information is given at

[www.adhd-congress.org/app/mobile](http://www.adhd-congress.org/app/mobile)



## TECHNICAL EXHIBITION

The 7<sup>th</sup> World Congress on ADHD will be accompanied by a technical exhibition taking place in Pavilion 4.

### Opening Hours

|                         |             |
|-------------------------|-------------|
| Thursday, 25 April 2019 | 15:00–21:00 |
| Friday, 26 April 2019   | 09:00–17:00 |
| Saturday, 27 April 2019 | 09:00–17:00 |
| Sunday, 28 April 2019   | 09:00–13:30 |

## POSTER EXHIBITION

All regular accepted posters are published as a supplement in *ADHD Attention Deficit and Hyperactivity Disorders* and are available as an electronic edition ([www.springer.com/12402](http://www.springer.com/12402)). All accepted posters are displayed in Pavilion 5. Posters are organized by topics into 28 guided poster tours (P-01 to P-28) which are numbered within these topics. Authors will be present to explain their work and answer questions. Each poster tour is chaired by an ADHD expert.

### Guided Poster tours take place:

#### P-01 – P-14

|                       |               |
|-----------------------|---------------|
| Friday, 26 April 2019 | 14:30 – 16:00 |
|-----------------------|---------------|

#### P-15 – P-28

|                         |               |
|-------------------------|---------------|
| Saturday, 27 April 2019 | 12:45 – 14:15 |
|-------------------------|---------------|

## GENERAL INFORMATION

### Set up times of posters

#### P-01 – P-14

Thursday, 25 April 2019 15:00 – 19:00

#### P-15 – P-28

Saturday, 27 April 2019 08:00 – 09:00

### Dismantling times of posters

#### P-01 – P-14

Friday, 26 April 2019 17:00 – 18:00

#### P-15 – P-28

Sunday, 28 April 2019 13:30 – 14:30

Posters which have not been removed within the indicated time schedule will be removed. **The poster size is 120 cm high and 90 cm wide** (portrait format). Poster authors are requested to use the adhesive material provided by the congress staff only.

### AWARDS

#### Young Scientists' Awards

Young Scientist's Sessions aim at encouraging young scientists to attend this interdisciplinary congress in the field of ADHD. The Scientific Committee has selected eight abstracts out of the submitted applications. The authors were invited to give a presentation as part of our two Young Scientists' Sessions. The sessions will be chaired by recognized experts for the featured topic. Speakers are requested to show a copy of their ID to prove, they are younger than 35 years of age. The winners will receive a young scientist award of EUR 500 each.

#### Poster Awards

Each chair of a poster tour chooses the best poster of the respective tour. These posters are displayed in the exhibition area in Hall 4, indicated by a banner. Among those, the Poster Committee will select six winners. The authors of the six best posters will be awarded at the closing ceremony, with a certificate and a prize money of 500 Euro

### SPEAKERS CENTRE

The Speakers Centre is located on the 1<sup>st</sup> floor in Room 1.14 & 1.09. Speakers are asked to hand in their CD ROM or USB stick, containing the PowerPoint preferably one day before their presentation but at the latest 90 minutes prior to the presentation. The presentation will be transferred to the central congress server and will be available afterwards on a special congress notebook in the hall of the presentation. Due to time and technical reasons we kindly ask the speakers not to use their own notebook. Several PC working stations are provided in the

speakers' centre where speakers can also work on their charts in a quiet area. Technical staff will be glad to assist.

operated by ESTENSIS GmbH –  
The Conference Buddies



### Opening Hours

|                         |               |
|-------------------------|---------------|
| Thursday, 25 April 2019 | 12:00 – 19:00 |
| Friday, 26 April 2019   | 07:30 – 17:00 |
| Saturday, 27 April 2019 | 08:00 – 17:00 |
| Sunday, 28 April 2019   | 08:00 – 13:00 |

### CAFETERIA/RESTAURANT

Refreshments and snacks can be bought at the cafeteria in Foyer D on the first floor.

The restaurant at the first floor offers set lunch on own expense in a quiet and nice atmosphere.

### COFFEE BREAKS

Coffee and tea are served during the designated coffee breaks, free of charge to all registered participants within the exhibition area.

### CLOAKROOM

A cloakroom is available in Foyer C next to the registration counter. You can also store your luggage there free of charge.

### BANK

An ATM machine is located within Foyer C.

### CURRENCY

The official currency is the EURO. Exchange of foreign currency is available at Lisbon airport and at most hotels, banks and exchange offices throughout the city.

### ELECTRICITY

The local voltage is 230 V with F plugs. A voltage converter and plug adapter is needed for US and UK appliances.

# GENERAL INFORMATION

## LOST AND FOUND

---

A lost and found service is available at the registration counter of the congress.

## MOBILE PHONES

---

Participants are kindly requested to keep their mobile phones turned off while attending the scientific sessions in the meeting rooms.

## PROGRAMME CHANGES

---

The organisers cannot assume liability for any changes in the congress programme due to external or unforeseen circumstances. In the event of cancellation by speakers or other changes in the main programme, no full or partial refund of the registration fee can be made.

## RECORDING

---

Cameras, video cameras or audio recording devices are not permitted in the session rooms. Any recording of sessions is strictly forbidden.

## CLIMATE

---

Lisbon has a mediterranean climate where temperatures can climb up to 26° C in April, with an average of 8 hours of sunshine per day.

## PRESS

---

Journalists should bring their press ID and register at the registration counter.

## INSURANCE

---

The congress fee does not include insurance. All participants should arrange for their own insurance. Health and accident insurance is recommended and has to be purchased in your country of origin.

## REGISTRATION CONDITIONS

---

The general conditions for the congress registration including payment and cancellation of the World Congress on ADHD are published on the congress website:

**[www.adhd-congress.org](http://www.adhd-congress.org)**

## PLACE OF PERFORMANCE, VENUE OF JURISDICTION

---

Lisbon, Portugal, shall be the exclusive place of performance and Hamburg, Germany, venue of jurisdiction for all parties. The laws of the Federal Republic of Germany shall apply.

## FORCE MAJEURE

---

For reasons beyond its control (such as war, strikes, lockouts, riots or any such civil disturbances, any acts of God, including but not limited to earthquakes, floods, droughts and typhoons and any other cause of circumstance of whatsoever nature beyond control) that have an impact on the arrangements, timetables or planning of the 7<sup>th</sup> World Congress on ADHD and its corresponding activities in Lisbon. The congress has the right to immediately alter or cancel the activities or events or any of the arrangements, timetables, plans or other items relating directly or indirectly thereto. No party involved shall be entitled to any compensation for damages that result from such alteration or cancellation.



## SATELLITE SYMPOSIA

Thursday, 25 April 2019

| SA-01                                      | Industry Sponsored Symposium  |
|--|---|
| <b>17:45–19:15</b>                         | <b>Auditorium II</b>  |
| <b>The unrecognized adult ADHD patient</b> |   |
| Chair:                                     | J. A. Ramos Quiroga, Spain  |
| SA-01-001                                  | Adult ADHD and accidents: Live (and drive) fast, die young?<br>A. Reif, Germany                     |
| SA-01-002                                  | The language of ADHD and its relevance in the diagnostic process<br>K. van Rensburg, United Kingdom |

*Supported by an unrestricted grant from MEDICE.*

Friday, 26 April 2019

| SA-02                        | Industry Sponsored Symposium  |
|------------------------------|---|
| <b>12:45–14:15</b>           | <b>Auditorium VI + VII</b>  |
| <b>ADHD: A family affair</b> |   |
| Chair:                       | D. Bull, United Kingdom   |
| SA-02-001                    | ADHD and comorbidities: Are they in the family genes?<br>P. Asherson, United Kingdom  |
| SA-02-002                    | Why family matters<br>D. Daley, United Kingdom  |
| SA-02-003                    | ADHD and the impact on family life<br>C. Enever, United Kingdom   |
| SA-02-004                    | Strategies for success in clinical practice: Managing ADHD in families<br>D. Daley, United Kingdom<br>S. Young, United Kingdom<br>J. Örnberg, Denmark |
|                              | <b>Moderated panel-audience discussion</b><br>K. Handelman, Canada<br>A. Philipsen, Germany<br>J. Quintero, Spain                                     |

*Supported by an unrestricted grant from Takeda.*

## ACKNOWLEDGEMENTS

The organizers of the 7<sup>th</sup> World Congress on ADHD gratefully acknowledge the support of the following companies (as per April 2019):

### MAJOR SPONSOR AND EXHIBITOR

Takeda




### FURTHER SPONSORS AND EXHIBITORS

- ▶ MEDICE
- ▶ neuroConn – neuroCare Group
- ▶ Soho Flordis International (SFI)
- ▶ The Tova Company
- ▶ Wisepress Medical Bookshop

# EXHIBITION MAP AND LIST OF EXHIBITORS

## EXHIBITION MAP



## LIST OF EXHIBITORS

| Company                                  | Booth No. |
|--|-----------|
| ADHD Europe                              | 4         |
| ADHD – World Federation of ADHD          | 2         |
| CADDRA                                   | 3         |
| MEDICE Arzneimittel Pütter GmbH & Co. KG | 7         |
| neuroConn – neuroCare Group              | 5         |
| Soho Flordis International (SFI)         | 8         |
| Takeda                                   | 9         |
| The Tova Company                         | 1         |
| Wisepress Medical Bookshop               | 6         |

## LIST OF CHAIRPERSONS AND PRESENTERS

|                                     |                |
|-------------------------------------|----------------|
| <b>A</b>                            |                |
| Abdeldayem, H. ....                 | 29             |
| Abdool Gafoor, L. ....              | 20             |
| Adamo, N. ....                      | 27             |
| Agnew-Blais, J. ....                | 36             |
| Ahnemark, E. ....                   | 35             |
| Alarcón de la Luz, E. M. ....       | 35             |
| Al-Menea, A. ....                   | 33             |
| Al-Otaibi, K. ....                  | 24             |
| Alves, D. ....                      | 33             |
| Alvim-Soares, A. ....               | 17             |
| Anker, E. ....                      | 22             |
| Aparecido de Araújo Afonso, C. .... | 20             |
| Arns, M. ....                       | 26             |
| Arruda, M. ....                     | 33             |
| Arseneault, L. ....                 | 36             |
| Asherson, P. ....                   | 14, 16, 28, 51 |
| Azouz, H. ....                      | 29, 33         |

|                            |                    |
|----------------------------|--------------------|
| <b>B</b>                   |                    |
| Bae, S.-M.                 | 20                 |
| Bahn, G.-H.                | 18, 19, 33         |
| Banaschewski, T.           | 16, 24, 27, 31, 39 |
| Band, A.                   | 31                 |
| Barragán Pérez, E.         | 31                 |
| Battistutta, L.            | 21                 |
| Bauer, K.                  | 19                 |
| Biederman, J.              | 14, 27, 28         |
| Bilbow, A.                 | 14                 |
| Bilke-Hentsch, O.          | 29                 |
| Blume, F.                  | 29                 |
| Blumenfeld Olivares, J. A. | 29                 |
| Boavida, J.                | 15, 37, 39         |
| Bolat, H.                  | 18                 |
| Bölte, S.                  | 14                 |
| Borg, J.                   | 19                 |
| Boricevic Marsanic, V.     | 29                 |
| Botanas, C.-J.             | 28                 |
| Brandeis, D.               | 26, 29             |
| Brikell, I.                | 16, 31             |
| Brock, S.                  | 35                 |
| Bröring-Starre, T.         | 14                 |
| Brown, D.                  | 36                 |
| Bryl, E.                   | 21                 |
| Buica, A. M.               | 20                 |
| Buitelaar, J. K.           | 16, 17, 28, 31, 37 |
| Bull, D.                   | 51                 |
| Bullock, R.                | 31                 |
| Butzbach, M.               | 23                 |

|                            |                        |
|----------------------------|------------------------|
| <b>C</b>                   |                        |
| Cardoso, J. ....           | 36                     |
| Carreiro, L. R. ....       | 23, 24, 30, 33         |
| Castellanos, F. X. ....    | 39                     |
| Castells Cervello, X. .... | 31                     |
| Caye, A. ....              | 17, 28, 36, 39         |
| Chamberlain, S. ....       | 16                     |
| Cheng, C.-Y. ....          | 20                     |
| Chen, T. ....              | 33                     |
| Chen, Y.-C. ....           | 24                     |
| Choi, J.-W. ....           | 24                     |
| Chou, W.-J. ....           | 22                     |
| Clement, C. ....           | 29                     |
| Coghill, D. ....           | 14, 15, 16, 27, 28, 30 |
| Cohen, J. ....             | 31                     |
| Colasanti, A. ....         | 25                     |
| Corbisiero, S. ....        | 36                     |
| Cortese, S. ....           | 27, 30, 38, 39         |

|                                 |    |
|---------------------------------|----|
| Costa, A. ....                  | 20 |
| Criaud, M. ....                 | 30 |
| Cristovam, M. A. da Silva ..... | 18 |
| Crunelle, C. ....               | 15 |

|                      |        |
|----------------------|--------|
| <b>D</b>             |        |
| Daley, D. ....       | 51     |
| Dalsgaard, S. ....   | 15, 37 |
| Danckaerts, M. ....  | 17     |
| Darini, M. ....      | 30     |
| Debost, M. ....      | 18     |
| Deiber, M.-P. ....   | 22     |
| De Leon, M. L. ....  | 34     |
| de Oliveira, I. .... | 30     |
| Diez Suárez, A. .... | 18     |
| Döpfner, M. ....     | 39     |
| Drechsler, R. ....   | 38     |

|                       |            |
|-----------------------|------------|
| <b>E</b>              |            |
| Edwards, S. J.        | 35         |
| Ellison, K.           | 17, 28, 39 |
| Enever, C.            | 51         |
| Ercan, E. S.          | 25         |
| Eskilsson Strålin, E. | 28         |

|                            |                    |
|----------------------------|--------------------|
| <b>F</b>                   |                    |
| Factor, R. ....            | 27                 |
| Fallgatter, A. ....        | 25, 26             |
| Faraone, S. ....           | 15, 17, 26, 28, 37 |
| Fehr, E. ....              | 36                 |
| Felinhofer, A. ....        | 30                 |
| Fernandez Reyes, D. ....   | 35                 |
| Ferraz de Liz, M. ....     | 22, 36             |
| Ferreira Carvalho, R. .... | 31                 |
| Ferreira, I. ....          | 15                 |
| Fletcher, E. ....          | 30                 |
| Forde, N. ....             | 27                 |
| Franke, B. ....            | 18, 26             |
| Franke, H. ....            | 17                 |
| Freitag, C. ....           | 22, 27             |
| French, B. ....            | 34                 |
| Fuermaier, A. B. M. ....   | 16                 |

|                              |        |
|------------------------------|--------|
| <b>G</b>                     |        |
| Galicia, E.....              | 24     |
| García Beristain, J. C. .... | 23     |
| Garcia Pimenta, M. ....      | 34     |
| Garcia Ribeiro, C.....       | 23     |
| Gau, S. ....                 | 14     |
| Geissler, J. ....            | 29, 37 |
| Gerlach, M.....              | 28     |
| Gnanavel, S. ....            | 31     |
| Gomes, R. ....               | 21     |
| Gonzalez, R. ....            | 30     |
| Graziano, P.....             | 19     |
| Gregersen, N. O. ....        | 18     |
| Grevet, E.....               | 36     |
| Grimm, O. ....               | 25     |
| Grimwade, J. ....            | 34     |
| Groen, Y. ....               | 19     |
| Grünblatt, E. ....           | 18     |
| Gunay Aksoy, S.....          | 19     |
| Guo, X. ....                 | 19     |
| Gurqel, W.....               | 32     |

**H**  
Haack, L..... 34

|                              |        |
|------------------------------|--------|
| Halldner Henriksson, L. .... | 32     |
| Halmøy, A. ....              | 29     |
| Halt, A.-H. ....             | 36     |
| Hamilton, A. ....            | 34     |
| Hanawa, Y. ....              | 32     |
| Hanc, T. ....                | 17     |
| Haugan, A.-L. Juul ....      | 24     |
| Hegerl, U. ....              | 27     |
| Helfer, B. ....              | 22     |
| Herman, B. ....              | 32     |
| Hershko, S. ....             | 34     |
| Herweg, S. ....              | 34     |
| Hess, J. ....                | 15     |
| Hirvikoski, T. ....          | 29     |
| Hoogman, M. ....             | 27, 28 |
| Hotakainen Dolan, M. ....    | 24     |
| Huang, Y.-J. ....            | 23     |
| Huss, M. ....                | 32     |

|                      |    |
|----------------------|----|
| Ibañez Soria, D..... | 23 |
| Icick, R.....        | 15 |
| Ilbegi, S.....       | 37 |
| Ipci, M.....         | 21 |
| Irimie-Ana, A.....   | 24 |
| Ismail, R. I.....    | 30 |
| Ito, W.....          | 23 |
| Iwanami, A.....      | 32 |

|                    |    |
|--------------------|----|
| <b>J</b>           |    |
| Jainer, R. ....    | 32 |
| Jin, J. ....       | 15 |
| Johansson, V. .... | 32 |

|                              |            |
|------------------------------|------------|
| <b>K</b>                     |            |
| Kando, J. ....               | 32         |
| Karlstad, Ø. ....            | 32         |
| Katzman, M. ....             | 20         |
| Kawabe, K. ....              | 32         |
| Keating, J. ....             | 24         |
| Kenter, R. ....              | 19         |
| Kerner auch Koerner, J. .... | 23         |
| Kestelman, I. ....           | 14         |
| Kiive, E. ....               | 21         |
| Kilic, O. ....               | 32         |
| Kim, B.-N. ....              | 18         |
| Kim, K. ....                 | 19         |
| Kittel-Schneider, S. ....    | 15, 35     |
| Klungsoyr, K. ....           | 15         |
| Koelle, M. ....              | 32         |
| Kok, F. ....                 | 24         |
| Kollins, S. H. ....          | 38, 39     |
| Kooij, S. ....               | 14, 16, 34 |
| Kowalczyk, O. ....           | 25         |
| Kuchler, I. ....             | 29         |
| Kuntsi, J. ....              | 14         |
| Kupnicka, Z. ....            | 34         |
| Kvitland, L. R. ....         | 20         |

|                     |        |
|---------------------|--------|
| <b>L</b>            |        |
| Lam, S.-L.          | 30     |
| Lara-Cabrera, M. L. | 29     |
| Larsson, H.         | 17     |
| Lee, C.             | 24     |
| Lee, M.-S.          | 34     |
| Lee, S.             | 16     |
| Lesch, K.-P.        | 18, 39 |

# LIST OF CHAIRPERSONS AND PRESENTERS

|                            |    |
|----------------------------|----|
| Lim, C. G. ....            | 30 |
| Linerós Linero, R. ....    | 17 |
| Li, T. ....                | 18 |
| Liu, C. K. ....            | 37 |
| Li, Y. ....                | 37 |
| Llorens Capdevila, M. .... | 24 |
| Lopes, A. ....             | 25 |
| Lundervold, A. J. ....     | 20 |
| Luo, X. ....               | 23 |
| Luque, T. ....             | 20 |
| Lynch, M. ....             | 34 |
| Lynn, N. ....              | 34 |

## M

|                          |            |
|--------------------------|------------|
| Macias, L. ....          | 22         |
| Mahone, M. ....          | 25         |
| Mamrot, P. ....          | 22         |
| Manor, I. ....           | 16, 27, 34 |
| Martin Garcia, L. ....   | 19         |
| Matias, J. ....          | 35         |
| Mattos, P. ....          | 14         |
| Mazhar, H. ....          | 32         |
| Meirelles Leite, F. .... | 23         |
| Meyers, R. ....          | 17, 20     |
| Mohler-Kuo, M. ....      | 15         |
| Moran, O. ....           | 34         |
| Moreno, M. ....          | 33, 34, 36 |
| Morris, S. ....          | 34         |
| Mpango, R. ....          | 19         |
| Mulraney, M. ....        | 37         |
| Mundal, I. ....          | 34         |

## N

|                          |    |
|--------------------------|----|
| Nakahara, R. ....        | 17 |
| Narad, M. E. ....        | 26 |
| Netzer Turgeman, R. .... | 23 |
| Neves, M. R. ....        | 27 |
| Newcorn, J. ....         | 39 |
| Ni, X. ....              | 28 |
| Nogueira, J. ....        | 23 |
| Nunes, L. ....           | 30 |

## O

|                  |        |
|------------------|--------|
| Örnberg, J. .... | 51     |
| Ohrmann, P. .... | 25     |
| Oh, Y.-H. ....   | 19, 36 |
| Ornoy, A. ....   | 17     |
| Oztop, D. ....   | 33     |

## P

|                          |            |
|--------------------------|------------|
| Palacio, J. D. ....      | 35         |
| Palacios Cruz, L. ....   | 19, 35     |
| Palm, D. ....            | 17         |
| Pan, M. ....             | 29         |
| Park, Y.-J. ....         | 23         |
| Paus, T. ....            | 26         |
| Peleikis, D. E. ....     | 20         |
| Pereira Antunes, M. .... | 20         |
| Pereira, D. ....         | 21, 35     |
| Philipsen, A. ....       | 14, 27, 28 |
| Pigeot, I. ....          | 26         |
| Polanczyk, G. ....       | 17         |
| Ponte, A. ....           | 14, 37     |
| Poznyak, E. ....         | 36         |
| Pypypow, J. ....         | 20         |

## Q

|                |        |
|----------------|--------|
| Quinn, D. .... | 15, 33 |
|----------------|--------|

## R

|                           |                |
|---------------------------|----------------|
| Ramos Quiroga, J. A. .... | 28, 37, 38, 51 |
| Ratajczak, J. ....        | 23             |
| Reif, A. ....             | 15, 35, 51     |
| Reimherr, F. ....         | 19, 36, 38     |
| Renner, T. ....           | 18             |
| Retz, W. ....             | 20, 27, 36     |
| Reuter, M. ....           | 34             |
| Ribases, M. ....          | 15             |
| Ribeiro, N. ....          | 22             |
| Riederer, P. ....         | 15, 28, 39     |
| Ringer, N. ....           | 34, 35         |
| Robaey, P. ....           | 31, 33, 35     |
| Rodopman Arman, A. ....   | 24, 35         |
| Rodrigues, A. ....        | 27, 37         |
| Rohde, L. A. ....         | 14, 39         |
| Roh, H.-S. ....           | 18             |
| Romanos, M. ....          | 20, 26, 28     |
| Rommelse, N. ....         | 15             |
| Rosetti, M. ....          | 36             |
| Roth Mota, N. ....        | 15             |
| Rubia, K. ....            | 24, 26         |
| Ruiz, M. ....             | 18, 33         |

## S

|                             |                |
|-----------------------------|----------------|
| Sá Carneiro, A. F. ....     | 17, 34         |
| Saez, B. V. ....            | 20             |
| Sahakian, B. ....           | 26             |
| Saito, T. ....              | 14             |
| Salmi, P. ....              | 31             |
| Sanabra, M. ....            | 30             |
| Sánchez-García, N. C. ....  | 22             |
| Sarver, D. ....             | 21             |
| Schwarz, U. ....            | 31             |
| Schweitzer, J. ....         | 26             |
| Sciberras, E. ....          | 14             |
| Seabra, A. ....             | 35             |
| Sedgwick, J. ....           | 14             |
| Seernani, D. ....           | 22             |
| Seleem, M. ....             | 18             |
| Sémelas Ledesma, J. M. .... | 24             |
| Sergeant, J. A. ....        | 23, 26         |
| Shih, H.-H. ....            | 33             |
| Shin, E.-B. ....            | 34             |
| Shoeman, R. ....            | 14             |
| Shoham, R. ....             | 21             |
| Shouo Lian, H.-G. ....      | 24             |
| Shuai, L. ....              | 31             |
| Sidenkova, A. ....          | 36             |
| Siebelink, N. ....          | 31             |
| Siemoneit, H. C. ....       | 25             |
| Silva, A. P. ....           | 28             |
| Simashkova, N. ....         | 18             |
| Siqueiros Sanchez, M. ....  | 24             |
| Sluiter, M. ....            | 30             |
| Söderlund, G. B. W. ....    | 31             |
| Solberg, B. S. ....         | 37             |
| Son, J.-W. ....             | 25             |
| Sonuga-Barke, E. ....       | 17             |
| Sorensen, L. ....           | 25             |
| Soualmia, I. ....           | 19             |
| Soutullo Esperon, C. ....   | 37, 39         |
| Stein, M. ....              | 14, 26, 27, 33 |
| Stergiakouli, E. ....       | 35             |
| Sternat, T. ....            | 19, 21         |

|                  |        |
|------------------|--------|
| Swanson, J. .... | 17, 38 |
|------------------|--------|

## T

|                         |        |
|-------------------------|--------|
| Tahillioglu, A. ....    | 20, 21 |
| Tan, Y. ....            | 25     |
| Teigen, A. M. ....      | 35     |
| Temelturk, R. D. ....   | 24     |
| Teodoro, T. ....        | 21     |
| Tessari, L. ....        | 22     |
| Thapar, A. ....         | 26     |
| Thome, J. ....          | 31     |
| Thygesen, M. ....       | 18     |
| Tourjman, S. V. ....    | 16     |
| Tovo-Rodrigues, L. .... | 26     |
| Trantou, A. ....        | 35     |
| Tucha, O. ....          | 16     |

## U

|                       |    |
|-----------------------|----|
| Ulberstad, F. ....    | 21 |
| Unterholzner, J. .... | 19 |

## V

|                              |        |
|------------------------------|--------|
| Vainieri, I. ....            | 23     |
| Vallejo Valdivielso, M. .... | 33     |
| van de Glind, G. ....        | 15, 22 |
| van de Lint, R. ....         | 29     |
| van Rensburg, K. ....        | 51     |
| van Rooij, D. ....           | 27     |
| Vanicek, T. ....             | 25     |
| Varela, P. ....              | 33     |
| Velez-Pastrana, M. ....      | 22     |
| Veloso, A. ....              | 31     |
| Verano de Oliveira, J. ....  | 35     |
| Vian, F. ....                | 21     |
| Vieira de Melo, B. ....      | 25     |

## W

|                         |            |
|-------------------------|------------|
| Walitza, S. ....        | 16, 21, 38 |
| Wang, Y. ....           | 37         |
| Warnke, A. ....         | 17, 22, 37 |
| Weber, L. ....          | 29         |
| Wehmeier, P. M. ....    | 19, 20     |
| Wei, C. ....            | 28         |
| Weiss, M. D. ....       | 14         |
| Werner-Kiechle, T. .... | 33         |
| Westwood, S. ....       | 29         |
| Wilczynski, K. M. ....  | 21, 22     |
| Wimberley, T. ....      | 15         |
| Wong, I. ....           | 17         |
| Wong, I. C. K. ....     | 26         |
| Wuestner, A. ....       | 18         |
| Wu, X. ....             | 25         |
| Wu, Z. ....             | 25         |

## X

|              |    |
|--------------|----|
| Xie, R. .... | 22 |
|--------------|----|

## Y

|                 |    |
|-----------------|----|
| Yang, J. ....   | 25 |
| Yemula, C. .... | 36 |
| Young, S. ....  | 51 |

## Z

|                    |            |
|--------------------|------------|
| Zhang, J. ....     | 21         |
| Zhang, M. ....     | 22         |
| Zheng-Tao, L. .... | 16         |
| Zheng, Y. ....     | 37         |
| Zhong, Y. ....     | 18, 19, 33 |
| Zuddas, A. ....    | 27, 32     |



CONGRESS AND EXHIBITION OFFICE

**CPO**HANSER®  
SERVICE

Hamburg Office

Hanser & Co GmbH

Zum Ehrenhain 34

22885 Barsbüttel, Germany

Phone: +49-40-670 88 20

Fax: +49-40-670 32 83

Email: [adhd2019@cpo-hanser.de](mailto:adhd2019@cpo-hanser.de)

[www.adhd-congress.org](http://www.adhd-congress.org)